News

Webcast Image Webcast
Q4 2023 IRIDEX Earnings Conference Call
03/26/24 at 5:00 PM EDT

Date Title Teaser
03/26/24
Summary ToggleIridex Reports Fourth Quarter and Full Year 2023 Financial Results Advances strategic review to unlock shareholder value MOUNTAIN VIEW, Calif. , March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma
03/20/24
Summary ToggleIridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024 MOUNTAIN VIEW, Calif. , March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release
02/06/24
Summary ToggleIridex Corporation Receives European Patent on MicroPulse Technology The Advanced Short Pulse Laser System MOUNTAIN VIEW, Calif. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal
01/24/24
Summary ToggleIridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust MOUNTAIN VIEW, Calif. , Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation , headquartered in Mountain View, California , and Imperial College Healthcare NHS Trust in London , today announced the first patient enrollment in a collaborative medical research study and registry evaluating the
01/11/24
Summary ToggleIridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma MOUNTAIN VIEW, Calif. , Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation , a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next-generation platform Iridex 532 ® and Iridex 577 ® Lasers alongside its 35 th
12/28/23
Summary ToggleIridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment MOUNTAIN VIEW, Calif. , Dec. 28, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for
11/27/23
Summary ToggleIridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation MOUNTAIN VIEW, Calif. , Nov. 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its successful
11/14/23
Summary ToggleIridex Reports Third Quarter 2023 Financial Results and Business Update MOUNTAIN VIEW, Calif. , Nov. 14, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results
11/13/23
Summary ToggleIridex to Host Third Quarter Financial Results Conference Call on November 14, 2023 The Company also announced plans to present at Stifel Healthcare Conference MOUNTAIN VIEW, Calif. , Nov. 13, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today
10/26/23
Summary ToggleIridex to Report Third Quarter Financial Results on November 14, 2023 MOUNTAIN VIEW, Calif. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2023
08/29/23
Summary ToggleIridex Announces Strategic Review to Unlock Shareholder Value MOUNTAIN VIEW, Calif. , Aug. 29, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) announced today that its Board of Directors is undertaking, in consultation with its financial and legal advisors, a review and evaluation of strategic alternatives that may be available to the Company to
08/10/23
Summary ToggleIridex Reports Second Quarter 2023 Financial Results MOUNTAIN VIEW, Calif. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 1, 2023 .
07/27/23
Summary ToggleIridex to Report Second Quarter Financial Results on August 10, 2023 MOUNTAIN VIEW, Calif. , July 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2023
05/11/23
Summary ToggleIridex Reports First Quarter 2023 Financial Results MOUNTAIN VIEW, Calif. , May 11, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today reported financial results for the first quarter ended April 1, 2023 .
04/27/23
Summary ToggleIridex to Report First Quarter Financial Results on May 11, 2023 MOUNTAIN VIEW, Calif. , April 27, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2023
03/09/23
Summary ToggleIridex Reports Fourth Quarter and Full Year 2022 Financial Results Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , March 09, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today
03/07/23
Summary ToggleIridex to Present at the 35th Annual Roth Conference MOUNTAIN VIEW, Calif. , March 07, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming 35 th Annual Roth Conference in
03/02/23
Summary ToggleIridex Introduces New Research and Showcases Five Events at the AGS Meeting Five Events at Booth #5 Discover the latest surgical techniques and outcomes published by the International MicroPulse TLT Consensus Panel . Watch Dr. Syril Dorairaj’s e-poster on prospective MicroPulse TLT dosimetry research outcomes. Demo Sweep Management Software for MicroPulse TLT.
02/23/23
Summary ToggleIridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023 MOUNTAIN VIEW, Calif. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and
01/10/23
Summary ToggleIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022 Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , Jan. 10, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today
12/06/22
Summary ToggleIridex to Participate in Fireside Chat with Stifel Equity Research MOUNTAIN VIEW, Calif. , Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat with its covering
11/10/22
Summary ToggleIridex Announces Record Third Quarter 2022 Financial Results Company Announces FDA Clearance of new Iridex Pascal® Scanning Laser Platform MOUNTAIN VIEW, Calif. , Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today
10/27/22
Summary ToggleIridex to Report Third Quarter 2022 Financial Results on November 10, 2022 MOUNTAIN VIEW, Calif. , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2022
09/29/22
Summary ToggleIridex Showcases its Non-Incisional Treatments for Glaucoma, Introduces Sweep Management Software, and Hosts 8 Physician Presentations at AAO 2022 MicroPulse ® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways to manage, preserve, and prolong vision for glaucoma patients.
08/18/22
Summary ToggleIridex to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase MOUNTAIN VIEW, Calif. , Aug. 18, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the company will present at the upcoming Inaugural Gilmartin Group
08/15/22
Summary ToggleIridex Announces Second Quarter 2022 Financial Results MOUNTAIN VIEW, Calif. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 2, 2022 . Second Quarter 2022 Highlights Total revenue of $13.8 million , an increase of 2% over the prior year period Gross Margin was
08/01/22
Summary ToggleIridex to Report Second Quarter 2022 Financial Results on August 15, 2022 MOUNTAIN VIEW, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of 2022
06/14/22
Summary ToggleIridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China MOUNTAIN VIEW, Calif. , June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6
05/12/22
Summary ToggleIridex Announces First Quarter 2022 Financial Results Achieved Record First Quarter Revenue MOUNTAIN VIEW, Calif. , May 12, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2, 2022 . First Quarter 2022 Highlights Record first quarter revenue of $13.4 million , an increase of
04/28/22
Summary ToggleIridex to Report First Quarter 2022 Financial Results on May 12, 2022 MOUNTAIN VIEW, Calif. , April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of
03/21/22
Summary ToggleIridex Announces the Appointment of Beverly Huss to its Board of Directors MOUNTAIN VIEW, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Beverly Huss to its board of directors, effective,
03/10/22
Summary ToggleIridex Announces Fourth Quarter and Full Year 2021 Financial Results Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , March 10, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 1, 2022 .
03/08/22
Summary ToggleIridex to Present at the 34th Annual Roth Conference MOUNTAIN VIEW, Calif. , March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 34 th Annual Roth
02/24/22
Summary ToggleIridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022 MOUNTAIN VIEW, Calif. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and
01/11/22
Summary ToggleIridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021 Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth MOUNTAIN VIEW, Calif. , Jan. 11, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended
11/12/21
Summary ToggleIridex to Present at the 2021 Stifel Virtual Healthcare Conference MOUNTAIN VIEW, Calif. , Nov. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming 2021 Stifel Virtual
11/11/21
Summary ToggleIridex Announces Third Quarter 2021 Financial Results Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance MOUNTAIN VIEW, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 2, 2021 . Third Quarter Highlights Revenue of $13.3 million ,
11/06/21
Summary ToggleRetina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021 Panel members scheduled for discussions at the Iridex booth during AAO meeting on November 13-15th MOUNTAIN VIEW, Calif. , Nov.
10/28/21
Summary ToggleIridex to Report Third Quarter 2021 Financial Results on November 11, 2021 MOUNTAIN VIEW, Calif. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the third quarter of 2021
09/30/21
Summary ToggleIridex to Present at the Lytham Partners Fall 2021 Investor Conference MOUNTAIN VIEW, Calif. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming Lytham Partners Fall
08/12/21
Summary ToggleIridex Announces Second Quarter 2021 Financial Results Achieved 116% Year-over-Year Revenue Growth and Record Cyclo G6 Probe Sales Increases Full Year 2021 Guidance MOUNTAIN VIEW, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July 3, 2021 .
08/09/21
Summary ToggleIridex to Present at the 2021 H.C. Wainwright Ophthalmology Virtual Conference MOUNTAIN VIEW, Calif. , Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in the upcoming H.C.
07/29/21
Summary ToggleIridex to Report Second Quarter 2021 Financial Results on August 12, 2021 MOUNTAIN VIEW, Calif. , July 29, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the second quarter of
05/11/21
Summary ToggleIridex Announces First Quarter 2021 Financial Results MOUNTAIN VIEW, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021 . First Quarter Highlights Closed strategic collaboration with Topcon Corporation netting $19.5 million in new funds Record first
04/27/21
Summary ToggleIridex to Report First Quarter 2021 Financial Results on May 11, 2021 MOUNTAIN VIEW, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of
03/22/21
Summary ToggleIridex Announces Fourth Quarter and Full Year 2020 Financial Results MOUNTAIN VIEW, Calif. , March 22, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2021 . Fourth Quarter Highlights Total revenue in the fourth quarter increased 5% to $12.3 million year-over-year Sold
03/10/21
Summary ToggleIridex Completes Transaction with Topcon Corporation MOUNTAIN VIEW, Calif. , March 10, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed the previously announced transaction with Topcon
03/08/21
Summary ToggleIridex to Report Fourth Quarter and Full Year 2020 Financial Results on March 22, 2021 MOUNTAIN VIEW, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the fourth quarter and
03/02/21
Summary ToggleIridex Announces Strategic Collaboration with Topcon Corporation Transaction provides $19.5 million cash to Iridex , as two leaders join forces in glaucoma and  retinal disease treatment Iridex to host a conference call presentation on March 2, 2021 at 2:00 p.m. PT / 5:00 p.m. ET MOUNTAIN VIEW, Calif. , March 02, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation
01/11/21
Summary ToggleIRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2020 MOUNTAIN VIEW, Calif. , Jan. 11, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 2, 2021 . Fourth Quarter 2020 Total revenue expected to be $12.2 million to $12.4
12/22/20
Summary ToggleIRIDEX Announces MicroPulse Transscleral Laser Therapy Now Accepted in the European Glaucoma Society Guidelines Guidelines provide recommendations on the diagnosis and management of glaucoma within the EU Nine MicroPulse TLT studies presented at the annual EGS meeting supporting its safety, effectiveness, and versatility in the treatment of glaucoma MOUNTAIN VIEW, Calif. , Dec.
11/09/20
Summary ToggleIRIDEX Announces Third Quarter 2020 Financial Results MOUNTAIN VIEW, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 26, 2020 . Third Quarter Summary Total revenue of $8.8 million , a decline of 17% versus $10.7 million in the prior year period, and an
11/03/20
Summary ToggleIRIDEX to Present at the 2020 Stifel Virtual Healthcare Conference MOUNTAIN VIEW, Calif. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Virtual Healthcare Conference . David I. Bruce , IRIDEX’s President and Chief Executive Officer, is scheduled to present on Tuesday,
10/26/20
Summary ToggleIRIDEX to Report Third Quarter 2020 Financial Results on November 9, 2020 MOUNTAIN VIEW, Calif. , Oct. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2020 after the close of trading on Monday, November 9, 2020 . The Company’s management team will host a corresponding
08/06/20
Summary ToggleIRIDEX Announces Second Quarter 2020 Financial Results MOUNTAIN VIEW, Calif. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 27, 2020 . Second Quarter Summary Total revenue declined 40% to $6.2 million versus $10.4 million in the prior year period Cost control
07/23/20
Summary ToggleIRIDEX to Report Second Quarter 2020 Financial Results on August 6, 2020 MOUNTAIN VIEW, Calif. , July 23, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2020 after the close of trading on Thursday, August 6, 2020 .  The Company’s management team will host a corresponding
05/11/20
Summary ToggleIRIDEX Announces First Quarter 2020 Financial Results MOUNTAIN VIEW, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 28, 2020 . Commenting on the recently completed quarter and the business environment created by the COVID-19 pandemic, David I.
04/28/20
Summary ToggleIRIDEX to Report First Quarter 2020 Financial Results on May 11, 2020 MOUNTAIN VIEW, Calif. , April 28, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2020 after the close of trading on Monday, May 11, 2020 . The Company’s management team will host a corresponding
04/21/20
Summary ToggleIRIDEX Announces the Appointment of Doris Engibous to its Board of Directors MOUNTAIN VIEW, Calif. , April 21, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the appointment of Doris Engibous to its board of directors effective
03/30/20
Summary ToggleIRIDEX ANNOUNCES RETIREMENT OF VP FINANCE Names Prior CFO/COO as Interim CFO MOUNTAIN VIEW, Calif. , March 30, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Romeo Dizon has retired from his
03/12/20
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2019 Financial Results MOUNTAIN VIEW, Calif. , March 12, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 28, 2019 . Fourth Quarter Highlights Cyclo G6® product family revenue grew 18% year-over-year to $3.7 million , or 31% of total revenue
02/28/20
Summary ToggleIRIDEX to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020 MOUNTAIN VIEW, Calif. , Feb. 28, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year of 2019 after the close of trading on Thursday, March 12, 2020 .  The Company’s management team will host a
02/26/20
Summary ToggleIRIDEX Launches Revised MicroPulse P3® Device for Glaucoma MOUNTAIN VIEW, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today the introduction of the second generation of the MicroPulse P3 ® Device,
01/13/20
Summary ToggleIRIDEX Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2019 MOUNTAIN VIEW, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 28, 2019 . Highlights Total revenue for the fourth quarter of 2019 expected to be $11.6 -
11/07/19
Summary ToggleIRIDEX Announces 2019 Third Quarter Financial Results MOUNTAIN VIEW, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 28, 2019 . Third Quarter Highlights Total revenue of $10.7 million Cyclo G6® product family revenue of $3.0 million , a 3.6%
11/05/19
Summary ToggleIRIDEX to Present at the 2019 Stifel Healthcare Conference MOUNTAIN VIEW, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Stifel Healthcare Conference in New York City . David I. Bruce , IRIDEX’s President and Chief Executive Officer, is scheduled to present on
10/28/19
Summary ToggleIRIDEX Announces Appointment of Robert Gunst as Chairman of the Board of Directors and Departure of Lead Independent Director, Ruediger Naumann-Etienne MOUNTAIN VIEW, Calif. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Robert Gunst as Chairman of the Board, effective October 23, 2019 . Concurrent with this appointment, Ruediger Naumann-Etienne departed from the Board of Directors as Lead
10/24/19
Summary ToggleIRIDEX to Report Third Quarter 2019 Financial Results on November 7, 2019 MOUNTAIN VIEW, Calif. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter of 2019 after the close of trading on Thursday, November 7 , 2019.  The Company’s management team will host a corresponding
09/11/19
Summary ToggleMicroPulse® Transscleral Laser Therapy Will be Discussed in Various Presentations and Educational Events at ESCRS 2019 in Paris, France MOUNTAIN VIEW, Calif. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its patented MicroPulse® laser therapy will be featured prominently
08/06/19
Summary ToggleIRIDEX Announces 2019 Second Quarter Financial Results MOUNTAIN VIEW, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 29, 2019 . Second Quarter Highlights Total revenue of $10.4 million ○  Cyclo G6 product family revenue of $3.4 million , an 11% increase
07/23/19
Summary ToggleIRIDEX to Report Second Quarter 2019 Financial Results on August 6, 2019 MOUNTAIN VIEW, Calif. , July 23, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter of 2019 after the close of trading on Tuesday, August 6 , 2019.  The Company’s management team will host a corresponding
05/21/19
Summary ToggleIRIDEX Announces Leadership Transition; David Bruce Appointed President and CEO MOUNTAIN VIEW, Calif. , May 21, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation  (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the appointment of David Bruce to be the company’s President and Chief
05/02/19
Summary ToggleIRIDEX Announces 2019 First Quarter Financial Results MOUNTAIN VIEW, Calif. , May 02, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 30, 2019 . First Quarter Highlights Total revenue of $10.6 million , an 11% increase year-over-year Cyclo G6® product revenue of $3.1 million
04/29/19
Summary ToggleIRIDEX’s MicroPulse® Laser Technology Featured in Several Glaucoma and Retina Research Presentations at Major Ophthalmic Industry Conferences MOUNTAIN VIEW, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its patented MicroPulse® technology played a pivotal role in
04/29/19
Summary ToggleScott Shuda Appointed to IRIDEX Board of Directors MOUNTAIN VIEW, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Scott Shuda has been appointed to its board of directors, effective
04/18/19
Summary ToggleIRIDEX to Report First Quarter 2019 Financial Results on May 2, 2019 MOUNTAIN VIEW, Calif. , April 18, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2019 after the close of trading on Thursday, May 2 , 2019.  The Company’s management team will host a corresponding
04/02/19
Summary ToggleKen Ludlum Appointed to IRIDEX Board of Directors MOUNTAIN VIEW, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that Ken Ludlum has been appointed to its Board of Directors, effective
04/01/19
Summary ToggleMicroPulse TSCPC featured in multiple abstracts, posters, presentations and wet lab at the World Glaucoma Congress
03/18/19
Summary ToggleIRIDEX to Present at the Spring Investor Summit MOUNTAIN VIEW, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming Spring Investor Summit in New York, NY . Chairman and CEO William Moore is scheduled to present on Monday, April 1, 2019 at 3:00 PM ET . 
03/06/19
Summary ToggleIRIDEX to Present at the 31st Annual Roth Conference MOUNTAIN VIEW, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming 31 st Annual Roth Conference in Orange County, CA. Management is scheduled to present on Tuesday, March 19, 2019 at 9:00 AM PT .  Interested
03/05/19
Summary ToggleIRIDEX Announces 2018 Fourth Quarter and Full Year Financial Results MOUNTAIN VIEW, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018 . Fourth Quarter Highlights Cyclo G6 ® product revenue increased approximately 16% year-over-year Shipped a record
02/26/19
Summary ToggleIRIDEX to Report Fourth Quarter and 2018 Financial Results on March 5, 2019 MOUNTAIN VIEW, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year 2018 after the close of trading on Tuesday, March 5 , 2019.  The Company’s management team will host a
02/12/19
Summary ToggleIRIDEX Announces Resolution of its Dispute with Quantel Medical MOUNTAIN VIEW, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has resolved its differences with Quantel Medical, S.A. , Quantel USA, Inc. , and Quantel, S.A. (collectively, “Quantel”) in its lawsuit filed against Quantel in the U.S.
01/08/19
Summary ToggleIRIDEX Announces Preliminary Operational and Financial Results for 2018 Fourth Quarter and Full Year MOUNTAIN VIEW, Calif. , Jan. 08, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018 . Highlights Shipped approximately 460 to 465 Cyclo G6® Glaucoma Laser Systems and
12/04/18
Summary ToggleIRIDEX Announces Departure of Chief Financial Officer and Reiterates Full Year 2018 Guidance MOUNTAIN VIEW, Calif. , Dec. 04, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced Chief Financial Officer Atabak Mokari will leave the Company for a senior finance executive role at another company. Mokari has agreed to assist in the orderly transition of his CFO
11/01/18
Summary ToggleIRIDEX Announces 2018 Third Quarter Financial Results and Raises Full Year 2018 Guidance MOUNTAIN VIEW, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 29, 2018 . Third Quarter Highlights Cyclo G6™ product revenue increased approximately 23% year-over-year Shipped 10,400
10/25/18
Summary ToggleIRIDEX to Participate in Upcoming Investor Conferences MOUNTAIN VIEW, Calif. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in upcoming investor conferences. IRIDEX’s management is scheduled to present at the Stephens NY Investment Conference on Wednesday, November 7 th , 2018 at
10/23/18
Summary ToggleLeading Ophthalmologists to Discuss the Value of IRIDEX Solutions at AAO Glaucoma and Retina Specialists Will Discuss the Benefits of MicroPulse® Technology MOUNTAIN VIEW, Calif. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation  (Nasdaq:IRIX), a leading provider of innovative laser systems in ophthalmology, will be hosting a series of panel discussions at the
10/18/18
Summary ToggleIRIDEX to Report Third Quarter 2018 Financial Results on November 1, 2018 MOUNTAIN VIEW, Calif. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the third quarter 2018 after the close of trading on Thursday, November 1 , 2018.  The Company’s management team will host a corresponding
10/15/18
Summary ToggleIRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors MOUNTAIN VIEW, Calif. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Dr. Robert Grove to the Company’s Board of Directors effective October 15, 2018 . Concurrently, Ann Rhoads will step down from the Board of Directors to focus attention on
09/14/18
Summary ToggleIRIDEX Announces Pricing of Public Offering of Common Stock MOUNTAIN VIEW, Calif. , Sept. 14, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions,
09/13/18
Summary ToggleIRIDEX Announces Proposed Public Offering of Common Stock MOUNTAIN VIEW, Calif. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) ("IRIDEX" or the "Company"), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions,
09/06/18
Summary ToggleIRIDEX Announces FDA Clearance to Introduce Updated TruFocus LIO Premiere™ Laser Accessory to the U.S. Market MOUNTAIN VIEW, Calif. , Sept. 06, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of its updated TruFocus LIO Premiere™ laser accessory following U.S. Food and Drug Administration ( FDA ) 510(k) review and clearance.   The TruFocus LIO Premiere is a light
08/30/18
Summary ToggleIRIDEX Cyclo G6™ Laser System for Glaucoma Treatment Used in Majority of Top U.S. Ophthalmology Hospitals Recent Study Published by U.S. News and World Report Highlighting the “Best Hospitals for Ophthalmology” Includes 35 IRIDEX Customers MOUNTAIN VIEW, Calif. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX ), a leading provider of innovative laser systems in ophthalmology, is
08/02/18
Summary ToggleIRIDEX Announces 2018 Second Quarter Results and Raises Full Year 2018 Guidance MOUNTAIN VIEW, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended June 30, 2018 . Second Quarter Highlights Cyclo G6™ product revenue increased approximately 58% year-over-year Shipped 11,500 G6
07/19/18
Summary ToggleIRIDEX to Report Second Quarter 2018 Financial Results on August 2, 2018 MOUNTAIN VIEW, Calif. , July 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter 2018 after the close of trading on Thursday, August 2 , 2018.  The Company’s management team will host a corresponding
07/10/18
Summary ToggleIRIDEX Reaches Milestone of 1000th Cyclo G6 System Shipped Important Commercial Milestone Demonstrates Growing Worldwide Awareness of MicroPulse Technology for Treatment of Glaucoma MOUNTAIN VIEW, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced that in the second quarter of 2018 it has shipped the 1,000th unit of
06/19/18
Summary ToggleIRIDEX Announces Approval of CYCLO G6™ Glaucoma Laser System in Korea MOUNTAIN VIEW, Calif. , June 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the approval of its CYCLO G6™ Glaucoma Laser system by South Korea's Ministry of Food and Drug Safety (MFDS).  Currently available in more than 50 countries, the CYCLO G6 treats patients
05/03/18
Summary ToggleIRIDEX Announces 2018 First Quarter Financial Results

MOUNTAIN VIEW, Calif. , May 03, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today reported financial results for the first quarter ended March 31, 2018 . First Quarter Highlights Cyclo G6™ product revenue increased approximately 50% year-over-year Shipped a record 11,600 G6 probes

04/19/18
Summary ToggleIRIDEX to Report First Quarter 2018 Financial Results on May 3, 2018

MOUNTAIN VIEW, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the first quarter 2018 after the close of trading on Thursday, May 3 , 2018.  The Company’s management team will host a corresponding conference

04/16/18
Summary ToggleIRIDEX Announces Appointment of Maria Sainz and David Bruce to its Board of Directors

MOUNTAIN VIEW, Calif. , April 16, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the appointment of Maria Sainz and David Bruce to the Company’s Board of Directors effective as of April 13 , 2018.  Ms. Sainz and Mr. Bruce will both join the Compensation Committee. Ms.

03/20/18
Summary ToggleIridex Receives CE Mark for Transilluminated Probe The leading-edge G-Probe Illuminate™ glaucoma device with built-in transillumination now available in Europe MOUNTAIN VIEW, Calif. , March 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) is pleased to announce the availability of the G-Probe Illuminate™ device in Europe .
03/08/18
Summary ToggleIRIDEX Announces 2017 Fourth Quarter and Full Year Financial Results Shipped Record Cyclo G6™ Laser Systems and G6 Probes MOUNTAIN VIEW, Calif. , March 08, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and full year ended December 30, 2017 . Fourth Quarter Highlights Fourth quarter 2017 revenue for
02/27/18
Summary ToggleIRIDEX to Present at the 30th Annual Roth Conference MOUNTAIN VIEW, Calif. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company plans to participate in the upcoming 30 th Annual Roth Conference in Orange County, CA. IRIDEX’s management is scheduled to present on Tuesday, March 13, 2018 at 11:00am PT . 
02/23/18
Summary ToggleIRIDEX Issues Voluntary Recall of TruFocus LIO Premiere™ Laser Indirect Ophthalmoscope Updates Preliminary Financial Results for 2017 Fourth Quarter and Full Year MOUNTAIN VIEW, Calif , Feb. 23, 2018 (GLOBE NEWSWIRE) -- On February 23, 2018 , IRIDEX Corporation (“Company”) initiated a voluntary recall of a specific laser accessory called the TruFocus LIO Premiere™.  The LIO is a
02/20/18
Summary ToggleIRIDEX to Report Fourth Quarter and 2017 Financial Results on March 8, 2018 MOUNTAIN VIEW, Calif. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8 , 2018.  The Company’s management team will host a
01/09/18
Summary ToggleIRIDEX Announces Infringement Lawsuit Against Quantel MOUNTAIN VIEW, Calif. , Jan. 09, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ:IRIX) announced today that it has filed a lawsuit against Quantel Medical, S.A., Quantel USA, Inc. , and Quantel, S.A. in the U.S. District Court for the Northern District of California .  The lawsuit alleges that
01/08/18
Summary ToggleIRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year MOUNTAIN VIEW, Calif. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 30, 2017 . Highlights Total revenue for the fourth quarter of 2017 expected to be $11.0 to
11/02/17
Summary ToggleIRIDEX Announces 2017 Third Quarter Financial Results MOUNTAIN VIEW, Calif. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today reported financial results for the third quarter and nine months ended September 30, 2017 . Third Quarter Highlights Record third quarter revenue of $10.9 million , an 11% year-over-year increase
10/26/17
Summary ToggleIRIDEX to Present at Upcoming Investor Conferences MOUNTAIN VIEW, Calif. , Oct. 26, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company plans to participate in two upcoming investor conferences. November 9, 2017 at 1:30pm ET , IRIDEX’s management is scheduled to present at the Canaccord Genuity Medical Technologies
10/19/17
Summary ToggleIRIDEX to Report Third Quarter 2017 Financial Results on November 2, 2017 MOUNTAIN VIEW, Calif. , Oct. 19, 2017 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the third quarter 2017 after the close of trading on Thursday, November 2 , 2017.  The Company’s management team will host a corresponding
08/03/17
Summary ToggleIRIDEX Announces 2017 Second Quarter, Six-Month Financial Results Updates Guidance for Full Year 2017 MOUNTAIN VIEW, Calif. , Aug. 3, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended July 1, 2017 . Second Quarter Financial Results and Highlights Total revenue of $10.0 million
07/20/17
Summary ToggleIRIDEX to Report Second Quarter 2017 Financial Results on August 3, 2017 MOUNTAIN VIEW, Calif. , July 20, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the second quarter 2017 after the close of trading on Thursday, August 3 , 2017.  The Company's management team will host a corresponding
07/18/17
Summary ToggleIRIDEX Announces Appointment Of Ann Rhoads To Its Board Of Directors MOUNTAIN VIEW, Calif. , July 18, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Ann Rhoads to the Company's Board of Directors, Audit Committee, and Compensation Committee, effective immediately. "We are delighted to add Ann to our Board of
05/24/17
Summary ToggleIRIDEX To Present At The Jefferies 2017 Global Healthcare Conference MOUNTAIN VIEW, Calif. , May 24, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the upcoming Jefferies 2017 Global Healthcare Conference in New York, NY . IRIDEX's management is scheduled to present on Wednesday, June 7, 2017 at
05/04/17
Summary ToggleIRIDEX Announces Presentation Of Data Demonstrating Safety And Efficacy Of Micropulse® Technology At Upcoming Industry Conferences Results will be highlighted at upcoming ASCRS congress May 5-9 and ARVO annual meeting May 7-11 MOUNTAIN VIEW, Calif. , May 4, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced the presentation of data demonstrating the safety and efficacy of its proprietary MicroPulse®
05/03/17
Summary ToggleIRIDEX Announces First Quarter 2017 Financial Results Updates Guidance for Full Year 2017 MOUNTAIN VIEW, Calif. , May 3, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the three months ended April 1, 2017 . Recent Financial Results and Highlights Total revenue of $10.5 million for the first quarter of
04/19/17
Summary ToggleIRIDEX to Report First Quarter 2017 Financial Results on May 3, 2017 MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release financial results for the first quarter 2017 after the close of trading on Wednesday, May 3 , 2017.  The Company's management team will host a corresponding
03/15/17
Summary ToggleIRIDEX To Present At The Sidoti & Co. Spring 2017 Convention MOUNTAIN VIEW, Calif. , March 15, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the Sidoti & Co. Spring 2017 Convention in New York, NY . Iridex's management is scheduled to present on Wednesday, March 29, 2017 at 3:00pm ET .
03/08/17
Summary ToggleIRIDEX Announces Fourth Quarter and 2016 Financial Results and Provides Full Year 2017 Financial Outlook Cyclo G6™ Glaucoma Laser Platform Fourth Quarter Revenue Up 67% Year-over-Year Record Revenue of $12.5 Million in the Fourth Quarter of 2016 MOUNTAIN VIEW, Calif. , March 8, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the three months and full year
02/28/17
Summary ToggleIRIDEX To Present At 29th Annual Roth Conference MOUNTAIN VIEW, Calif. , Feb. 28, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to participate in the 29 th Annual Roth Conference in Orange County, CA. Iridex's management is scheduled to present on Tuesday, March 14, 2017 at 9:30am PT .
02/28/17
Summary ToggleIRIDEX Launches New FDA-Cleared Probe At The Annual American Glaucoma Society Meeting The award winning CYCLO G6™ Glaucoma Laser System now offers a treatment with built-in transillumination MOUNTAIN VIEW, Calif. , Feb. 28, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) is pleased to announce the availability of the G-Probe™ Illuminate, a new, FDA -cleared probe offering
02/22/17
Summary ToggleIRIDEX to Report Fourth Quarter and 2016 Financial Results on March 8, 2017 MOUNTAIN VIEW, Calif. , Feb. 22, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release financial results for the fourth quarter and 2016 after the close of trading on Wednesday, March 8 , 2017.  The Company's management team will host a corresponding
01/31/17
Summary ToggleBioTuesdays: Iridex MicroPulse Probes Glaucoma Continuum of Care
01/09/17
Summary ToggleIRIDEX Announces Preliminary Unaudited Revenues for 2016 Fourth Quarter and Full Year MOUNTAIN VIEW, Calif. , Jan. 9, 2017 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported preliminary revenues of approximately $12.4 to $12.5 million and $46.0 to $46.1 million for the fourth quarter and full year 2016, respectively, meeting the previously provided quarterly and
12/09/16
Summary ToggleIRIDEX Corporation Prices Public Offering of Common Stock MOUNTAIN VIEW, Calif. , Dec. 9, 2016 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced the pricing of its underwritten public offering of an aggregate of 1.15 million shares of common stock at a price of $14.00 per share, $0.01 par value (the "Offering" with such shares being
12/08/16
Summary ToggleIRIDEX Corporation Announces Proposed Public Offering of Common Stock MOUNTAIN VIEW, Calif. , Dec. 8, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it intends to offer newly issued shares of common stock, $0.01 par value (the "Offering" with such shares being the "Shares") pursuant to an underwritten public offering.
11/07/16
Summary ToggleIRIDEX to Present at Upcoming Investor Conferences MOUNTAIN VIEW, Calif. , Nov. 7, 2016 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that management is scheduled to present at the following investor conferences in New York City : The Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17,
11/03/16
Summary ToggleIRIDEX Reports 2016 Third Quarter, Nine-Month Results Cyclo G6™ Glaucoma Laser Platform Third Quarter Revenues Up 442 Percent Year-over-Year MOUNTAIN VIEW, Calif. , Nov. 3, 2016 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended October 1 , 2016.  Revenues were $9.8
10/27/16
Summary ToggleIRIDEX Announces Third Quarter 2016 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Oct. 27, 2016 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2016 financial results after the market closes on Thursday, November 3, 2016 .   In conjunction with the release, the Company will host a
10/11/16
Summary ToggleIRIDEX Announces Preliminary Revenues for 2016 Third Quarter MOUNTAIN VIEW, Calif. , Oct. 11, 2016 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported preliminary revenues of approximately $9.6 to $9.7 million for the third quarter ended October 1, 2016 compared to prior revenue guidance of $11.0 to $11.3 million .  While demand for
09/07/16
Summary ToggleIRIDEX Announces Long-Term Glaucoma Efficacy Data for Patients Treated with MicroPulse® P3 Probe Technology Follow-up data published at European Glaucoma Society (EGS) meeting highlight six and a half years of efficacy data in patients with refractory glaucoma MOUNTAIN VIEW, Calif. , Sept. 7, 2016 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX), a leading global provider of innovative laser
08/04/16
Summary ToggleIRIDEX Reports 2016 Second Quarter, Six-Month Results Total Revenues Up 32 Percent Year-over-Year for Second Quarter; Cyclo G6™ Glaucoma Laser System Revenues Up 66 Percent Sequentially MOUNTAIN VIEW, Calif. , Aug. 4, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended
07/28/16
Summary ToggleIRIDEX Announces Second Quarter 2016 Conference Call and Release Date MOUNTAIN VIEW, Calif. , July 28, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2016 financial results after the market closes on Thursday, August 4, 2016 .   In conjunction with the release, the Company will host a conference
07/11/16
Summary ToggleIRIDEX Announces Atabak Mokari Will Be Chief Financial Officer And VP Corporate Development MOUNTAIN VIEW, Calif. , July 11, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that Atabak Mokari , 39, will join the Company as Chief Financial Officer and Vice President of Corporate Development effective July 11, 2016 . Mr.
06/02/16
Summary ToggleIRIDEX to Present at the Singular Research 11th Annual Best of the Uncovereds Spring Select Conference MOUNTAIN VIEW, Calif. , June 2, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that President and CEO Will Moore is scheduled to present at the Singular Research 11 th
05/10/16
Summary ToggleIRIDEX Announces Cyclo G6™ with MicroPulse® P3 Clinical Data Presented at ARVO and ASCRS Annual Meetings Data underscore safety and efficacy of non-invasive tissue-sparing technology in patients with glaucoma MOUNTAIN VIEW, Calif. , May 10, 2016 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology,
05/05/16
Summary ToggleIRIDEX Reports 2016 First Quarter Results Record First Quarter Revenues Revenues Up 11 Percent Versus First Quarter of 2015 MOUNTAIN VIEW, Calif. , May 5, 2016 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 2 , 2016.  Revenues were $11.9 million for the first quarter of
04/28/16
Summary ToggleIRIDEX Announces First Quarter 2016 Conference Call and Release Date MOUNTAIN VIEW, Calif. , April 28, 2016 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2016 financial results after the market closes on Thursday, May 5, 2016 .   In conjunction with the release, the Company will host a conference call with
03/22/16
Summary ToggleIRIDEX Gains Patent Approvals Covering TxCell™-Guided MicroPulse® Laser Therapy; Predictably Enables Faster, Durable Treatments for Glaucoma and Retinal Diseases MOUNTAIN VIEW, Calif. , March 22, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, announced today that the United States Patent Office issued the Company two new patent approvals for
03/03/16
Summary ToggleIRIDEX Reports 2015 Fourth Quarter, Full Year Results Revenues Up 3 Percent versus Fourth Quarter of 2014 Revenues Up 23 Percent Sequentially for Fourth Quarter MOUNTAIN VIEW, Calif. , March 3, 2016 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2 , 2016.    Revenues
02/25/16
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2015 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Feb. 25, 2016 /PRNewswire/ --   IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its fourth quarter and full year 2015 financial results after the market closes on Thursday, March 3, 2016 .   In conjunction with the release, the Company will host a
02/16/16
Summary ToggleIRIDEX Receives CE Mark for Cyclo G6™ Laser System for the Treatment of Multiple Stages of Glaucoma European Roll-Out Follows Successful Launch in US Market; System Placements and Utilization Surpass Expectations MOUNTAIN VIEW, Calif. , Feb. 16, 2016 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX), a leading global provider of innovative laser systems, delivery devices and consumables in
01/11/16
Summary ToggleIRIDEX Announces Preliminary Unaudited Revenues for 2015 Fourth Quarter and Full Year Year-End Strength in Both Glaucoma and Retinal Laser Systems and Procedures MOUNTAIN VIEW, Calif. , Jan. 11, 2016 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $11.9 to $12.2 million and $41.5 to $41.8 million for the fourth quarter and full
11/11/15
Summary ToggleIRIDEX to Showcase Cyclo G6™ Laser System Equipped with MicroPulse® Tissue Sparing Glaucoma Technology at American Academy of Ophthalmology (AAO) Meeting Glaucoma System to Make First Ever AAO Appearance at 119th Annual Meeting MOUNTAIN VIEW, Calif. , Nov. 11, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced its attendance at the 119 th annual American Academy of Ophthalmology (AAO) Meeting .
11/05/15
Summary ToggleIRIDEX Reports 2015 Third Quarter, Nine-Month Results MOUNTAIN VIEW, Calif. , Nov. 5, 2015 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended October 3 , 2015.    Revenues were $9.8 million in the third quarter of 2015 compared to $10.1 million in the 2014 third quarter and
10/29/15
Summary ToggleIRIDEX Announces Third Quarter 2015 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Oct. 29, 2015 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2015 financial results after the market closes on Thursday, November 5, 2015 .   In conjunction with the release, the Company will host a conference call
09/08/15
Summary ToggleIRIDEX Broadens Global Glaucoma Outreach With Novel Eye Pressure Diagnostic Device Icare's Tonometer for Monitoring Intra-Ocular Pressure Adds to Recurring Revenue Stream MOUNTAIN VIEW, Calif. , Sept. 8, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced that it has added a novel intra-ocular pressure (IOP) monitoring device called a tonometer to its suite of
08/06/15
Summary ToggleIRIDEX Reports 2015 Second Quarter, Six-Month Results MOUNTAIN VIEW, Calif. , Aug. 6, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended July 4 , 2015.  Revenues were $9.0 million in the second quarter of 2015 compared to $10.6 million in the 2014 second
08/04/15
Summary ToggleIRIDEX Chief Financial Officer Resigns to Accept Another Opportunity MOUNTAIN VIEW, Calif. , Aug. 4, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today announced that James H. Mackaness , who had served as chief financial officer since 2008 and as chief operating officer since 2012, has resigned his positions with the Company, effective August 21, 2015 ,
07/30/15
Summary ToggleIRIDEX Announces Second Quarter 2015 Conference Call and Release Date MOUNTAIN VIEW, Calif. , July 30, 2015 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2015 financial results after the market closes on Thursday, August 6, 2015 .   In conjunction with the release, the Company will host a conference
07/16/15
Summary ToggleIRIDEX Announces Preliminary Revenues for 2015 Second Quarter MOUNTAIN VIEW, Calif. , July 16, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $9.0 to $9.1 million and $19.8 to $19.9 million for the second quarter and first six months 2015, respectively.
05/28/15
Summary ToggleIRIDEX to Present at LD Micro Invitational MOUNTAIN VIEW, Calif. , May 28, 2015 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that Chief Operating Officer and Chief Financial Officer James H. Mackaness is scheduled to present at the LD Micro Invitational on Wednesday, June 3, 2015 , at 9:00 am PT in Los Angeles .
05/13/15
Summary ToggleIRIDEX to Present at UBS Global Healthcare Conference MOUNTAIN VIEW, Calif. , May 13, 2015 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that management is scheduled to present at the UBS Global Healthcare Conference on Tuesday, May 19, 2015 , at 9:00 am ET in New York City . A live audio webcast of the presentation may be
05/07/15
Summary ToggleIRIDEX Reports 2015 First Quarter Results Record Q1 Revenues MOUNTAIN VIEW, Calif. , May 7, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 4 , 2015.  Revenues were $10.8 million in the first quarter of 2015, up 5% from $10.3 million in the 2014 first
04/30/15
Summary ToggleIRIDEX Announces First Quarter 2015 Conference Call and Release Date MOUNTAIN VIEW, Calif. , April 30, 2015 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2015 financial results after the market closes on Thursday, May 7, 2015 .   In conjunction with the release, the Company will host a conference
04/16/15
Summary ToggleIRIDEX' Total Glaucoma Solution Campaign for US Market to Debut at Annual Congress of the American Society of Cataract and Refractive Surgery Solution includes IQ 532™ Laser for Repeatable MicroPulse® Laser Trabeculoplasty and the New Cyclo G6™ System with the Proprietary MicroPulse P3 Disposable MOUNTAIN VIEW, Calif. , April 16, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today announced the debut of its Total Glaucoma
03/30/15
Summary ToggleIRIDEX Granted U.S. Patent for Disposable Device for Efficient and Predictable Wound Closure in Eye Surgeries New iClip™ Closure Device Focused on Glaucoma with Broadening Applications in Other Specialties of Ophthalmology MOUNTAIN VIEW, Calif. , March 30, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today announced that the United States Patent and Trademark Office granted the Company a
03/17/15
Summary ToggleIRIDEX Announces First Commercial Sales of New Cyclo G6™ Glaucoma Laser Systems Initial Orders Include the Recently Patented MicroPulse® P3 Disposable Probe MOUNTAIN VIEW, Calif. , March 17, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of
03/05/15
Summary ToggleIRIDEX Reports 2014 Fourth Quarter, Year-End Results Record Revenues for the Quarter and the Year MOUNTAIN VIEW, Calif. , March 5, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 3 , 2015.  Revenues were $11.8 million in the fourth quarter of 2014, a
02/26/15
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Feb. 26, 2015 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its fourth quarter and full year 2014 financial results after the market closes on Thursday, March 5, 2015 .   In conjunction with the release, the Company will host a
02/23/15
Summary ToggleIRIDEX To Debut Cyclo G6™ Glaucoma Laser Platform and Present New Clinical Data at the American Glaucoma Society's Annual Meeting Laser Platform Supports Family of Consumable Probes and Appliances Including Recently Patented MicroPulse® P3 Disposable MOUNTAIN VIEW, Calif. , Feb. 23, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced that it will debut Cyclo G6, the Company's first laser platform
02/02/15
Summary ToggleIRIDEX Receives FDA Clearance for Cyclo G6™ Laser System for the Treatment of Multiple Stages of Glaucoma MicroPulse® Technology Offers Minimally Invasive, Repeatable Treatment Option that Can Slow Progression of Disease; Delay Surgical Intervention MOUNTAIN VIEW, Calif. , Feb. 2, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today announced that it has received clearance from the U.S.
01/12/15
Summary ToggleIRIDEX Announces Preliminary Unaudited Revenues for 2014 Fourth Quarter and Full Year; 2015 Revenue Outlook MOUNTAIN VIEW, Calif. , Jan. 12, 2015 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $11.5 to $11.7 million and $42.5 to $42.7 million for the fourth quarter and full year 2014, respectively.
12/31/14
Summary ToggleMedical Laser Veteran George R. Marcellino, Ph.D. Appointed to IRIDEX Board of Directors MOUNTAIN VIEW, Calif. , Dec. 31, 2014 /PRNewswire/ --  IRIDEX Corporation (NASDAQ:IRIX) announced today that it has appointed ophthalmology and medical laser executive George R. Marcellino , Ph.D., to its Board of Directors, effective immediately. Dr.
11/19/14
Summary ToggleIRIDEX Secures Large Tender from Government of Zambia for Ophthalmology Laser Equipment Expanding Tender Activity in Developing Economies Demonstrates Recognition of Low Cost, Durable Therapeutic Advantages of Laser-Based Treatments for Ophthalmologic Diseases MOUNTAIN VIEW, Calif. , Nov. 19, 2014 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) announced today that it has been
10/30/14
Summary ToggleIRIDEX Reports 2014 Third Quarter, Nine-Month Results MOUNTAIN VIEW, Calif. , Oct. 30, 2014 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter and nine months ended September 27 , 2014.  Revenues were $10.1 million in the third quarter of 2014, a record for the company's third quarter
10/23/14
Summary ToggleIRIDEX Announces Third Quarter 2014 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Oct. 23, 2014 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2014 financial results after the market closes on Thursday, October 30, 2014 .   In conjunction with the release, the Company will host a
10/17/14
Summary ToggleIRIDEX to Host MicroPulse® Worldwide 3-Day Forum at the American Academy of Ophthalmology Fourteen Physicians, Eight New to the IRIDEX Podium, will Share their Experiences using MicroPulse® Laser Therapy for Retina and Glaucoma MOUNTAIN VIEW, Calif. , Oct. 17, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today its Speakers' Forum program at the annual meeting of the
10/14/14
Summary ToggleIRIDEX Expands Retinal Portfolio MOUNTAIN VIEW, Calif. , Oct. 14, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) announced today that it will introduce its new family of patented Adjustable & Intuitive Extended Reach (A&I XR) laser probes at the annual meeting of the American Academy of Ophthalmology to be held
10/07/14
Summary ToggleIRIDEX Granted U.S. Patent for Disposable MicroPulse® Delivery Device for the Non-invasive Treatment of Glaucoma MOUNTAIN VIEW, Calif. , Oct. 7, 2014 /PRNewswire/ --  IRIDEX Corporation (NASDAQ:IRIX) today announced that the United States Patent and Trademark Office granted the company a patent for a new proprietary disposable delivery device. The disposable delivery device, the first of its kind, enables
10/01/14
Summary ToggleIRIDEX Reports Strong Attendance at European Workshop for its Proprietary MicroPulse® Laser Therapy for Retina and Glaucoma Applications More than 150 Physicians in Attendance MOUNTAIN VIEW, Calif., Oct. 1, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX ) today reported a strong physician presence and reception at this year's joint congress of the European Society of Retina Specialists (EURETINA) and European Society of
08/27/14
Summary ToggleIRIDEX to Present at Robert W. Baird 2014 Health Care Conference MOUNTAIN VIEW, Calif. , Aug. 27, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that COO and CFO James H. Mackaness is scheduled to make an investor presentation at the Robert W. Baird 2014 Health Care Conference at 2:55 p.m. Eastern Time on Wednesday, September 3 , in New
08/07/14
Summary ToggleDirector Garrett A. Garrettson, Ph.D. to Step Down After Decade-Long Service MOUNTAIN VIEW, Calif. , Aug. 7, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX ) today announced that, after more than a decade of service, Garrett A. Garrettson has resigned his seat on the IRIDEX Board of Directors. President and CEO Will Moore said, "Garry's insight and guidance on
08/05/14
Summary ToggleIRIDEX to Present at 2014 Wedbush Life Sciences Management Access Conference MOUNTAIN VIEW, Calif. , Aug. 5, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that President and CEO Will Moore is scheduled to make an investor presentation at the 2014 Wedbush Life Sciences Management Access Conference at 1:55 p.m.
07/31/14
Summary ToggleIRIDEX Reports 2014 Second Quarter, Six-Month Results Revenue Up 15% Year over Year for Both Periods Board of Directors Establishes New Share Repurchase Program MOUNTAIN VIEW, Calif. , July 31, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter and six months ended June 28 , 2014.  Revenues
07/24/14
Summary ToggleIRIDEX Announces Second Quarter 2014 Conference Call and Release Date MOUNTAIN VIEW, Calif. , July 24, 2014 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2014 financial results after the market closes on Thursday, July 31, 2014 . In conjunction with the release, the Company will host a conference call with
05/22/14
Summary ToggleIRIDEX Announces New Multi-Center Study Data Demonstrates Safety, Durability of Proprietary MicroPulse™ Technology for Treatment of Glaucoma MOUNTAIN VIEW, Calif. , May 22, 2014 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced that data from a one-year, multi-center study demonstrates the safety and durability of its proprietary MicroPulse technology as a treatment for glaucoma.
05/01/14
Summary ToggleIRIDEX Reports 2014 First Quarter Results Revenue Up 16% to $10.3 Million Year over Year MOUNTAIN VIEW, Calif. , May 1, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX ) today reported financial results for the first quarter ended March 29 , 2014.  Revenues were $10.3 million in the first quarter of 2014, up 16% from $8.9 million in
04/24/14
Summary ToggleIRIDEX Announces First Quarter 2014 Conference Call and Release Date MOUNTAIN VIEW, Calif., April 24, 2014 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2014 financial results after the market closes on Thursday, May 1, 2014 .   In conjunction with the release, the Company will host a conference call
04/22/14
Summary ToggleIRIDEX Announces Proprietary MicroPulse™ Technology For Treatment Of Eye Diseases Caused By Diabetes And Age-Related Macular Degeneration Featured On 'American Health Front' Program Innovative, Tissue-Sparing, Cost-Effective Therapy MOUNTAIN VIEW, Calif. , April 22, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that an educational story based on its innovative MicroPulse™ technology for the treatment of diabetic macular edema (DME) and age-related
04/10/14
Summary ToggleLow-Priced Stock Buys: New Treatments For Eye Disease, Respiratory Difficulties
03/31/14
Summary ToggleVIDEO: MicroPulse Laser Therapy showcased on American Health Front
02/27/14
Summary ToggleIRIDEX Reports 2013 Fourth Quarter Results Record Revenue of $10.6 Million in Quarter MOUNTAIN VIEW, Calif. , Feb. 27, 2014 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 28 , 2013.  Revenues were $10.6 million in the fourth quarter of 2013, up 15% from
02/20/14
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2013 Conference Call and Release Date MOUNTAIN VIEW, Calif., Feb. 20, 2014 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its fourth quarter and full year 2013 financial results after the market closes on Thursday, February 27, 2014 .   In conjunction with the release, the Company will
01/28/14
Summary ToggleIRIDEX Announces Preliminary Unaudited Revenues For 2013 Fourth Quarter and Year End MOUNTAIN VIEW, Calif. , Jan. 28, 2014 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today reported preliminary revenues of approximately $10.6 million and $38.3 million for the fourth quarter and full year 2013, respectively. Preliminary revenues in the fourth quarter exceeded the high end of
11/13/13
Summary ToggleIRIDEX To Introduce Four New Products At Annual AAO Meeting Fifteen physicians, seven new to the IRIDEX podium, will discuss their experiences using MicroPulse™ for retinal and glaucoma therapies MOUNTAIN VIEW, Calif. , Nov. 13, 2013 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today announced that it would introduce four new products at the annual
11/07/13
Summary ToggleIRIDEX Promotes Timothy D. Buckley to Vice President of Marketing and North American Sales MOUNTAIN VIEW, Calif. , Nov. 7, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced that, effective immediately, it has promoted sales and marketing executive Timothy D. Buckley to Vice President of Marketing and North American Sales.
11/06/13
Summary ToggleIRIDEX - In The Early Innings Of Margin Expansion
10/31/13
Summary ToggleIRIDEX Reports 2013 Third Quarter Results RECORD REVENUE OF $9.5 MILLION IN QUARTER MOUNTAIN VIEW, Calif. , Oct. 31, 2013 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 28 , 2013.  Revenues were $9.5 million in the third quarter of 2013, up 21% from $7.9 million in
10/30/13
Summary ToggleIRIDEX CEO William Moore discusses how Latin America fits into the global marketing strategy by addressing the socioeconomic differences. Click to see full interview.
10/24/13
Summary ToggleIRIDEX Announces Third Quarter 2013 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Oct. 24, 2013 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2013 financial results after the market closes on Thursday, October 31, 2013 .   In conjunction with the release, the Company will host a conference call
09/26/13
Summary ToggleUpcoming Global Medical Conferences to Feature IRIDEX Proprietary MicroPulse™ Laser Therapy Durable Clinical Effect, Substantial Economic Benefits Support Global Opportunity for Tissue-Sparing Solution MOUNTAIN VIEW, Calif. , Sept. 26, 2013 /PRNewswire/ --  IRIDEX (Nasdaq: IRIX) today announced a number of key international conferences and workshops that will feature its proprietary
09/17/13
Summary ToggleIRIDEX to Present at Craig-Hallum 4th Annual Alpha Select Conference MOUNTAIN VIEW, Calif. , Sept. 17, 2013 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that management is scheduled to make an investor presentation at the Craig-Hallum 4th Annual Alpha Select Conference at 9:10 am EDT on Thursday, September 26 .
08/06/13
Summary ToggleIRIDEX to Present at 2013 Wedbush Securities Life Sciences Management Access Conference MOUNTAIN VIEW, Calif. , Aug. 6, 2013 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that management is scheduled to make an investor presentation at 2013 Wedbush Securities Life Sciences Management Access Conference at 3:40 pm EDT on Tuesday, August 13 .
08/01/13
Summary ToggleIRIDEX Reports 2013 Second Quarter Results; $9.2 Million Record Q2 Revenue MOUNTAIN VIEW, Calif. , Aug. 1, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 29 , 2013.  Revenues were $9.2 million in the second quarter of 2013, up from $8.4 million in the prior year comparable period and up
07/25/13
Summary ToggleIRIDEX Announces Second Quarter 2013 Conference Call and Release Date MOUNTAIN VIEW, Calif. , July 25, 2013 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2013 financial results after the market closes on Thursday, August 1, 2013 .   In conjunction with the release, the Company will host a conference call
06/11/13
Summary ToggleIRIDEX Announces Automatic Conversion of Series A Preferred Stock to Common Stock MOUNTAIN VIEW, Calif. , June 11, 2013 /PRNewswire/ --   IRIDEX Corporation (Nasdaq: IRIX) today announced that it has converted all outstanding shares of its Series A Preferred Stock into 1,000,000 shares of its common stock. The Series A Preferred shares were issued to BlueLine
05/16/13
Summary ToggleIRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit Funds Released from Escrow Account Marks Final Chapter in Sale MOUNTAIN VIEW, Calif. , May 16, 2013 /PRNewswire/ --  IRIDEX Corporation (Nasdaq:IRIX) today announced that it has received the final $510,000 cash payment from the February 2012 sale of its aesthetic business unit.
05/02/13
Summary ToggleIRIDEX Reports 2013 First Quarter Results Profits Increase as Commercial Progress and Operational Streamlining Continue MOUNTAIN VIEW, Calif. , May 2, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 30, 2013 . Ophthalmology revenues in the first quarter were $8.9
04/30/13
Summary ToggleIRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries Orders from BRIC Countries Demonstrate Cost, Durable Therapeutic Advantages of Laser-Based Treatments for Ophthalmologic Diseases MOUNTAIN VIEW Calif. , April 30, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced that it has recently received two significant orders for its
04/25/13
Summary ToggleIRIDEX Announces First Quarter 2013 Conference Call and Release Date MOUNTAIN VIEW, Calif. , April 25, 2013 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2013 financial results after the market closes on Thursday, May 2, 2013 .   In conjunction with the release, the Company will host a conference
04/02/13
Summary ToggleIRIDEX Announces Global Distribution and Supply Agreement with Peregrine Surgical, Ltd. Agreement to broaden IRIDEX' ophthalmology surgical product portfolio and enhance manufacturing supply chain efficiencies MOUNTAIN VIEW, Calif. , April 2, 2013 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced that it has entered into a global distribution and supply agreement
02/28/13
Summary ToggleIRIDEX Reports Record 2012 Fourth Quarter Results Board Approves New $3.0 Million Stock Repurchase Program MOUNTAIN VIEW, Calif. , Feb. 28, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 29, 2012 . Ophthalmology revenues in the fourth quarter were $9.2 million ,
02/21/13
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2012 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Feb. 21, 2013 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its fourth quarter and full year 2012 financial results after the market closes on Thursday, February 28, 2013 .
01/22/13
Summary ToggleIRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End MOUNTAIN VIEW, Calif. , Jan. 22, 2013 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) reported preliminary revenues of approximately $9.2 million and $33.8 million for the fourth quarter and full year 2012, respectively.  Revenues in the fourth quarter exceeded the high end of the
12/14/12
Summary ToggleIRIDEX Corporation Announces Final Results of its Tender Offer MOUNTAIN VIEW, Calif. , Dec. 14, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today the final results of its tender offer to purchase up to 487,500 shares of its common stock at a purchase price of $4.10 per share, which expired at 5:00 p.m.
12/10/12
Summary ToggleIRIDEX Corporation Announces Preliminary Results of its Tender Offer MOUNTAIN VIEW, Calif. , Dec. 10, 2012 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) announced today the preliminary results of its tender offer to purchase up to 487,500 shares of its common stock at a purchase price of $4.10 per share, which expired at 5:00 p.m.
12/03/12
Summary ToggleIRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases TxCell™ Scanning Laser Delivery System capable of multi-spot, single spot, and Fovea-friendly™ MicroPulse Laser Therapy MOUNTAIN VIEW, Calif. , Dec. 3, 2012 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced the FDA 510(k) and CE clearance of the TxCell Scanning Laser Delivery
11/09/12
Summary ToggleIRIDEX Signs Global Licensing Agreement with QUANTEL Medical IRIDEX' patented MicroPulse™ laser technology enables Fovea-friendly™ therapy for sight-threatening eye diseases MOUNTAIN VIEW, Calif. , Nov. 9, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that IRIDEX and QUANTEL Medical have signed a global patent licensing agreement
11/07/12
Summary ToggleIRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock MOUNTAIN VIEW, Calif. , Nov. 7, 2012 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced that it expects to commence a tender offer to purchase up to 487,500 shares of its common stock at a purchase price of $4.10 per share. The number of shares proposed to be purchased in
11/01/12
Summary ToggleIRIDEX Reports 2012 Third Quarter Results MOUNTAIN VIEW, Calif. , Nov. 1, 2012 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 29, 2012 .   Ophthalmology revenues in the third quarter were $7.9 million , compared to $8.3 million in the prior year period.
10/25/12
Summary ToggleIRIDEX Announces Third Quarter 2012 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Oct. 25, 2012 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2012 financial results after the market closes on Thursday, November 1, 2012 .   In conjunction with the release, the Company will host a
08/28/12
Summary ToggleIRIDEX Appoints Chairman William M. Moore as Interim President & CEO CFO James Mackaness to Assume COO Responsibilities MOUNTAIN VIEW, Calif. , Aug. 28, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that its board of Directors has named medical device industry veteran William M. Moore ., age 63, as interim President and Chief Executive
08/02/12
Summary ToggleIRIDEX Reports 2012 Second Quarter Results MOUNTAIN VIEW, Calif. , Aug. 2, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 30, 2012 . Due to the sale of the Company's aesthetics laser business in February 2012 , the Company's financial statements reflect the results
07/26/12
Summary ToggleIRIDEX Announces Second Quarter 2012 Conference Call and Release Date MOUNTAIN VIEW, Calif. , July 26, 2012 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2012 financial results after the market closes on Thursday, August 2, 2012 .   In conjunction with the release, the Company will host a conference
06/06/12
Summary ToggleIRIDEX Announces First Endo-MicroPulse™ Laser Surgery Performed with the IQ 577™ Laser and EndoProbe® Instrumentation MOUNTAIN VIEW, Calif. , June 6, 2012 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced the use of MicroPulse™ Laser Therapy (MPLT), using the IQ 577 laser coupled with EndoProbe® instrumentation, that was successfully
05/03/12
Summary ToggleIRIDEX Reports 2012 First Quarter Results MOUNTAIN VIEW, Calif. , May 3, 2012 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 31, 2012 . Due to the sale of the Company's aesthetics laser business in February 2012 , the Company's financial statements reflect the
04/27/12
Summary ToggleIRIDEX Introduces Non-Invasive MicroPulse(TM) Therapy for Glaucoma Tissue-Sparing, Repeatable MicroPulse Laser Trabeculoplasty (MLT) Extends Versatility of IRIDEX Green (IQ 532) Laser MOUNTAIN VIEW, Calif., April 27, 2012 /PRNewswire via COMTEX/ -- IRIDEX Corporation today announced the launch of a new non-invasive, in-office glaucoma procedure based on its
04/26/12
Summary ToggleIRIDEX Announces First Quarter 2012 Conference Call and Release Date MOUNTAIN VIEW, Calif., April 26, 2012 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its first quarter 2012 financial results after the market closes on Thursday, May 3, 2012 . In conjunction with the release, the Company will host a conference
03/02/12
Summary ToggleIRIDEX to Present at Upcoming Investment Conferences MOUNTAIN VIEW, Calif. , March 2, 2012 /PRNewswire/ --  IRIDEX Corporation (NASDAQ: IRIX) today announced that management is scheduled to make investor presentations at investment conferences this month. The Company presents today at the Lazard Capital Markets Annual Medical Technology Snowbird
03/01/12
Summary ToggleIRIDEX Reports 2011 Fourth Quarter and Year-End Results MOUNTAIN VIEW, Calif. , March 1, 2012 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today reported financial results for the fourth quarter ended December 31, 2011 . Due to the sale of the Company's aesthetics laser business in February 2012 , the Company will be reporting its results for its
02/23/12
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2011 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Feb. 23, 2012 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its fourth quarter and full year 2011 financial results after the market closes on Thursday, March 1, 2012 .   In conjunction with the release, the Company will host a
02/03/12
Summary ToggleIRIDEX and Cutera Close Acquisition of IRIDEX' Aesthetic Business Unit MOUNTAIN VIEW, Calif. , Feb. 3, 2012  /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that IRIDEX and Cutera, Inc. (NASDAQ: CUTR) have closed their previously announced purchase agreement for Cutera to acquire IRIDEX ' aesthetic business for approximately $5.1 million .
01/25/12
Summary ToggleIRIDEX MicroPulse™ Laser Therapy Enhances Visual Function in Patients with Central Serous Chorioretinopathy (CSC) Study concluded tissue-sparing subvisible MicroPulse laser is superior to anti-VEGF injections for eye disease that most commonly affects men ages 20-50. MOUNTAIN VIEW, Calif. , Jan. 25, 2012 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) announced results of a clinical study evaluating
01/09/12
Summary ToggleSidoti Conference 2012 Presentation
01/04/12
Summary ToggleIRIDEX to Present at the Sidoti & Company New York Micro Cap Conference MOUNTAIN VIEW, Calif. , Jan. 4, 2012 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that CEO Dominik Beck is scheduled to make an investor presentation at the Sidoti & Company , LLC Annual New York Micro Cap Conference on Monday, January 9 , at 10:00 am Eastern Time . 
01/03/12
Summary ToggleCutera and IRIDEX Announce Acquisition of IRIDEX' Aesthetic Business Unit Purchase positions Cutera as a leader in the vascular aesthetic market; and refocuses IRIDEX on core ophthalmology opportunity BRISBANE and MOUNTAIN VIEW, Calif. , Jan. 3, 2012 /PRNewswire/ --  Cutera, Inc. (NASDAQ: CUTR) and IRIDEX Corporation (NASDAQ: IRIX) today announced that the companies
12/13/11
Summary ToggleUK's National Health System Rejects Drug Therapy for Diabetic Macular Edema Ruling Advances Opportunity for IRIDEX' Tissue Sparing MicroPulse ™ Laser Therapy MOUNTAIN VIEW, Calif. , Dec. 13, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that the United Kingdom 's National Institute for Health and Clinical Excellence (NICE) has issued a final
12/12/11
Summary Toggle10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema Results show innovative tissue-sparing laser therapy creates durable therapeutic effect without the damage caused by traditional laser techniques MOUNTAIN VIEW, Calif. , Dec. 12, 2011 /PRNewswire/ --  IRIDEX Corporation (Nasdaq: IRIX) today announced that data from a clinical study(1) compiled
11/15/11
Summary ToggleIRIDEX Signs License and Distribution Agreement with Leader in Eye Care Agreement Covers Certain Vitrectomy Instrumentation on a Worldwide Basis MOUNTAIN VIEW, Calif. , Nov. 15, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) announced it has entered into a license and distribution agreement with Alcon, the global leader in eye care, headquartered in Fort Worth,
11/03/11
Summary ToggleIRIDEX Reports 2011 Third Quarter and Nine-Month Results MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended October 1, 2011 . Revenues were $10.8 million , gross margins were 45.4% and operating expenses were $4.4 million for the third quarter of
10/27/11
Summary ToggleIRIDEX Announces Third Quarter 2011 Conference Call and Release Date MOUNTAIN VIEW, Calif., Oct. 27, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its third quarter 2011 financial results after the market closes on Thursday, November 3, 2011 . In conjunction with the release, the Company will host a conference
10/19/11
Summary ToggleIRIDEX Launches New MicroPulse(TM) Module Targeting the Broad Ophthalmology Laser Photocoagulation Market Patented Technology Enables Greater Control of Laser Therapy, Less Damage to Tissue MOUNTAIN VIEW, Calif., Oct. 19, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that it has expanded its product offering by introducing an optional MicroPulse module in the
10/10/11
Summary ToggleIRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO Theodore A. Boutacoff Named CTO to Lead Effort to Commercialize Innovative MicroPulse Technology MOUNTAIN VIEW, Calif., Oct. 10, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) (the "Company") today announced that Dominik Beck has been named President and Chief Executive Officer
09/20/11
Summary ToggleIRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc. Agreement Will Bolster New Initiatives in Glaucoma Market MOUNTAIN VIEW, Calif., Sept. 20, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company
08/31/11
Summary ToggleIRIDEX Expands ENT Laser Applications New XP Module(TM) Option available for the IQ 532(TM) Green Laser for Otolaryngology and Ophthalmology MOUNTAIN VIEW, Calif., Aug. 31, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) announced the introduction of its new XP Module - a high power factory installed option for the
08/04/11
Summary ToggleIRIDEX Reports Growing Revenue and Profits in 2011 Second Quarter MOUNTAIN VIEW, Calif., Aug. 4, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported improved financial results for the second quarter ended July 2, 2011 . For the second quarter of 2011: earnings increased 13% to $0.9 million or $0.09 per diluted share, up from $0.8
07/28/11
Summary ToggleIRIDEX Announces Second Quarter 2011 Conference Call and Release Date MOUNTAIN VIEW, Calif., July 28, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2011 financial results after the market closes on Thursday, August 4, 2011 . In conjunction with the release, the Company will host a conference
05/05/11
Summary ToggleIRIDEX Reports Growing Revenue and Profits in 2011 First Quarter Announces Stock Repurchase Program MOUNTAIN VIEW, Calif., May 5, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported that growing demand for new products and consumables drove sales and improved financial results for the first quarter ended April 2, 2011 .
05/04/11
Summary ToggleStudy Demonstrates Benefits of MicroPulse(TM) Photocoagulation Over Current Standard Laser Treatment of Diabetic Macular Edema MOUNTAIN VIEW, Calif., May 4, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that leading clinicians have performed and published the results of a new study* that compares the benefits of MicroPulse photocoagulation technology, similar to that used in the new
05/02/11
Summary ToggleIRIDEX Granted U.S. Patent for Stepped Angled Laser Handpieces Used in Eye Surgery Stepped Angled EndoProbe® Product Line is Best Selling IRIDEX Consumable MOUNTAIN VIEW, Calif., May 2, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that the U.S. Patent and Trademark Office had issued to IRIDEX a patent applying to a group of specially designed
04/28/11
Summary ToggleIRIDEX Announces First Quarter 2011 Conference Call and Release Date MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its first quarter 2011 financial results after the market closes on Thursday, May 5, 2011 . In conjunction with the release, the Company will host a conference
03/07/11
Summary ToggleIRIDEX to Present at the Roth OC Growth Stock Conference in Dana Point, CA MOUNTAIN VIEW, Calif., March 7, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that management is scheduled to make an investor presentation at the ROTH 23rd Annual OC Growth Stock Conference on Monday, March 14 , at 2:30 pm Pacific Time .
03/03/11
Summary ToggleIRIDEX Reports Strong Growth and Profits in 2010 Fourth Quarter Quarterly Profit increases 62% as Sales and Gross Margins Strengthen Record Operating Income and Strong Cash Generation for the Year MOUNTAIN VIEW, Calif., March 3, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported that growing demand for new products and consumables
03/02/11
Summary ToggleIRIDEX Purchases Remaining Common Stock Held by American Medical Systems Holdings, Inc. MOUNTAIN VIEW, Calif., March 2, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has purchased 75,698 shares of IRIDEX Common Stock from American Medical Systems Holdings, Inc. (Nasdaq: AMMD) (AMS). The shares are the remaining holdings of IRIDEX Common
02/24/11
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2010 Conference Call and Release Date MOUNTAIN VIEW, Calif., Feb. 24, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its fourth quarter and full year 2010 financial results after the market closes on Thursday, March 3, 2011 . In conjunction with the release, the Company will host
01/06/11
Summary ToggleIRIDEX to Present at the OneMedForum San Francisco 2011 Conference MOUNTAIN VIEW, Calif., Jan. 6, 2011 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that management will present at the OneMedForum San Francisco 2011 Conference at 8:45 a.m. PST on Tuesday, January 11 . The conference will be held on January 11-13 at the Sir Francis
11/04/10
Summary ToggleIRIDEX Reports Improved Third Quarter 2010 Financial Results -- Exceeded Q3 guidance -- Sales increased 4.0% over same period last year and 9.4% sequentially -- Net income of $0.9 million or $0.09 per diluted share MOUNTAIN VIEW, Calif., Nov. 4, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third
10/28/10
Summary ToggleIRIDEX Announces Third Quarter 2010 Conference Call and Release Date MOUNTAIN VIEW, Calif., Oct 28, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its third quarter 2010 financial results after the market closes on Thursday, November 4, 2010. In conjunction with the release, the Company will host a conference
10/11/10
Summary ToggleIRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe(R) Device for Eye Surgery MOUNTAIN VIEW, Calif., Oct 11, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery.
10/05/10
Summary ToggleIRIDEX Begins Shipment of Extended EndoProbe(R) Device Family to Japan Japan Ministry of Health, Labour and Welfare Approves IRIDEX EndoProbe Portfolio MOUNTAIN VIEW, Calif., Oct 05, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced approval and commercial availability in Japan for its extended family of EndoProbe laser delivery
08/18/10
Summary ToggleIRIDEX Granted U.S. Patent for MicroPulse(TM) Technology - A Fine Dose Control Technology Enabling Tissue Sparing Eye Surgeries With Visible Lasers MOUNTAIN VIEW, Calif., Aug 18, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the receipt of issuance of U.S. Patent No. 7,771,417, titled "Laser System with Short Pulse Characteristics And Its Method Of Use." This patent applies to the company's MicroPulse(TM)
08/05/10
Summary ToggleIRIDEX Reports Second Quarter 2010 Financial Results Sixth consecutive quarter of operating income Cash flow positive from operations Net income of $0.8 million or $0.08 per diluted share MOUNTAIN VIEW, Calif., Aug 05, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended July
07/29/10
Summary ToggleIRIDEX Announces Second Quarter 2010 Conference Call and Release Date MOUNTAIN VIEW, Calif., July 29, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its second quarter 2010 financial results after the market closes on Thursday, August 5, 2010. In conjunction with the release, the Company will host a conference
07/29/10
Summary ToggleIRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery MOUNTAIN VIEW, Calif., July 29, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the receipt of an Issue Notification from the U.S. Patent and Trademark Office for U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent
06/17/10
Summary ToggleStudy Demonstrates that IRIDEX MicroPulse Laser Effectively Treats Eyes with Diabetic Macular Edema Results Show Improved Retinal Sensitivity Compared to Standard Laser Treatment MOUNTAIN VIEW, Calif., June 17, 2010 /PRNewswire via COMTEX/ --IRIDEX Corporation (Nasdaq: IRIX) announced the recent publication of a clinical study comparing results obtained in the treatment of diabetic macular edema
05/06/10
Summary ToggleIRIDEX Reports First Quarter 2010 Financial Results First quarter GAAP Earnings per Share increases 150% Paid off Bank Debt MOUNTAIN VIEW, Calif., May 6, 2010 /PRNewswire via COMTEX/ --IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2010. For the first quarter of 2010, the Company recorded a
04/30/10
Summary ToggleIRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems Second New Laser Introduced within One Year Based on Common Platform MOUNTAIN VIEW, Calif., April 30, 2010 /PRNewswire via COMTEX/ --IRIDEX Corporation, (Nasdaq: IRIX) today announced the commencement of commercial shipment of the IQ 532 laser systems.
04/29/10
Summary ToggleIRIDEX Announces First Quarter 2010 Conference Call and Release Date MOUNTAIN VIEW, Calif., April 29, 2010 /PRNewswire via COMTEX/ --IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its first quarter 2010 financial results after the market closes on Thursday, May 6, 2010. In conjunction with the release, the Company will host a conference call
04/09/10
Summary ToggleIRIDEX Acquires Ophthalmology Products from RetinaLabs, Inc. Acquisition Expected to be Accretive MOUNTAIN VIEW, Calif., April 9, 2010 /PRNewswire via COMTEX/ --IRIDEX Corporation (Nasdaq: IRIX) today announced that it has acquired certain assets from RetinaLabs, Inc., a privately held company based in Atlanta, Georgia.
03/04/10
Summary ToggleIRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results - Fourth Consecutive Profitable Quarter - Record Operating Income for the Year - Generated $6.8 Million of Cash for the Year MOUNTAIN VIEW, Calif., March 4, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and full year ended
02/25/10
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date MOUNTAIN VIEW, Calif., Feb 25, 2010 /PRNewswire via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its fourth quarter and full year 2009 financial results after the market closes on Thursday, March 4, 2010. In conjunction with the release, the Company will host a
12/18/09
Summary ToggleRuediger Naumann-Etienne Appointed to IRIDEX Board of Directors MOUNTAIN VIEW, Calif., Dec 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today the appointment of Ruediger Naumann-Etienne to its Board of Directors. "Rudi brings to our Board 25 years of experience in growing medical device companies," said Theodore A.
11/12/09
Summary ToggleIRIDEX Reports Third Quarter 2009 Financial Results Third Consecutive Profitable Quarter MOUNTAIN VIEW, Calif. , Nov. 12 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter of 2009 ended October 3, 2009 . For the third quarter of 2009, the Company recorded a net profit of $0.6 million or
11/05/09
Summary ToggleIRIDEX Announces Third Quarter 2009 Conference Call and Release Date MOUNTAIN VIEW, Calif. , Nov. 5 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its third quarter 2009 financial results after the market closes on Thursday, November 12, 2009 . In conjunction with the release, the Company will host a conference call
10/21/09
Summary ToggleIRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology MOUNTAIN VIEW, Calif. , Oct. 21 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of a Modular Multi-Wavelength laser photocoagulator solution, which will be featured at the 2009 American Academy of Ophthalmology meeting in San Francisco .
10/21/09
Summary ToggleIRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology MOUNTAIN VIEW, Calif. , Oct. 21/PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of the IQ 532(TM) dual-port ophthalmic green laser photocoagulator which will be featured at the 2009 American Academy of Ophthalmology meeting in San Francisco .
10/01/09
Summary ToggleIRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting MOUNTAIN VIEW, Calif. , Oct. 1 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of FlexFiber(TM) a laser fiber probe intended for effective delivery of laser energy during ear, nose and throat (ENT) procedures.
08/13/09
Summary ToggleIRIDEX Reports Second Quarter 2009 Financial Results Second Consecutive Profitable Quarter MOUNTAIN VIEW, Calif., Aug 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter of 2009 ended July 4, 2009. For the second quarter of 2009, the Company recorded a net profit of
08/06/09
Summary ToggleIRIDEX Announces Second Quarter 2009 Conference Call and Release Date MOUNTAIN VIEW, Calif ., Aug. 6 /PRNewswire-FirstCall/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2009 financial results after the market closes on Thursday, August 13, 2009 . In conjunction with the release, the Company will host a conference call
05/14/09
Summary ToggleIRIDEX Reports First Quarter 2009 Financial Results MOUNTAIN VIEW, Calif ., May 14 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter of 2009 ended April 4, 2009 . For the first quarter of 2009 the Company recorded a net profit of $0.2 million or $0.03 per diluted share compared to a
05/07/09
Summary ToggleIRIDEX Announces First Quarter 2009 Conference Call and Release Date MOUNTAIN VIEW, Calif ., May 7 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its first quarter 2009 financial results after the market closes on Thursday, May 14, 2009 . In conjunction with the release, the Company will host a conference call with
04/30/09
Summary ToggleIRIDEX Announces Shipment of New IQ 577(TM) Laser Systems New Technology Represents First True Yellow Laser with CW-Pulse(TM) and MicroPulse(TM) Delivery MOUNTAIN VIEW, Calif ., April 30 /PRNewswire-FirstCall/ -- IRIDEX Corporation , (Nasdaq: IRIX) today announced the commencement of shipments to customers of the IQ 577 laser systems.
03/10/09
Summary ToggleIRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results MOUNTAIN VIEW, Calif ., March 10 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported its financial results for the fourth quarter and full fiscal year ended January 3, 2009 . Revenues for the fourth quarter of 2008 were $12.1 million , a 14.1% decrease from the $14.1 million
03/03/09
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2008 Conference Call and Release Date MOUNTAIN VIEW, Calif ., March 3 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its fourth quarter and full year 2008 financial results after the market closes on Tuesday, March 10, 2009 . In conjunction with the release, the Company will host a
11/04/08
Summary ToggleIRIDEX Reports Third Quarter 2008 Financial Results MOUNTAIN VIEW, Calif., Nov. 4 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the third quarter ended September 27, 2008. Revenue for the third quarter of 2008 was $12.0 million, an 11.7% decrease from the $13.6 million reported for the third quarter
10/28/08
Summary ToggleIRIDEX Announces Third Quarter 2008 Conference Call and Release Date MOUNTAIN VIEW, Calif., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its third quarter 2008 financial results after the market closes on Tuesday, November 4, 2008.
08/15/08
Summary ToggleIRIDEX Announces FDA Clearance for New Product Family of IRIDEX IQ Laser Systems MOUNTAIN VIEW, Calif., Aug. 15 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announces receipt of FDA 510(k) clearance for its Family of IRIDEX IQ Laser Systems. This clearance covers the IRIDEX IQ 532, IQ 577, IQ 630-670, and IQ 810 Laser Systems and their associated delivery devices
08/12/08
Summary ToggleIRIDEX Reports Second Quarter 2008 Financial Results MOUNTAIN VIEW, Calif., Aug. 12 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the second quarter ended June 28, 2008. Revenue for the second quarter of 2008 was $12.9 million, a 15.3% decrease from the $15.2 million reported for the second quarter
08/05/08
Summary ToggleIRIDEX Announces Second Quarter 2008 Conference Call and Release Date MOUNTAIN VIEW, Calif., Aug. 5 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its second quarter 2008 financial results after the market closes on Tuesday, August 12, 2008. In conjunction with the release, the Company will host a conference call with
05/13/08
Summary ToggleIRIDEX Reports First Quarter 2008 Financial Results MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter of 2008 ended March 29, 2008. Revenue for the first quarter of 2008 was $11.5 million, an 8.7% decrease from the $12.6 million reported for the first
05/08/08
Summary ToggleIRIDEX Announces First Quarter 2008 Conference Call and Release Date MOUNTAIN VIEW, Calif., May 8 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its first quarter 2008 financial results after the market closes on Tuesday, May 13, 2008. In conjunction with the release, the Company will host a conference call with the
04/10/08
Summary ToggleIRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results MOUNTAIN VIEW, Calif., April 10 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported final financial results for the fourth quarter and full year ended December 29, 2007. Revenue for the fourth quarter of 2007 was $14.1 million, a 56.5% increase from the $9.0 million reported
04/02/08
Summary ToggleIRIDEX Announces Completion of New Loan Facility With Wells Fargo Bank MOUNTAIN VIEW, Calif., April 2, 2008, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced completion of an $8.0 million loan facility with Wells Fargo Bank which replaces its previous loan facilities with Mid-Peninsula Bank.
03/28/08
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date MOUNTAIN VIEW, Calif., March 28 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its fourth quarter and full year 2007 financial results after the market closes on Thursday, April 10, 2008. In conjunction with the release, the Company will host a
12/17/07
Summary ToggleIRIDEX Announces James Mackaness Will Be Chief Financial Officer MOUNTAIN VIEW, Calif., Dec. 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that James H. Mackaness, 44, will join the Company as Chief Financial Officer effective January 2, 2008. Mr. Mackaness is currently Chief Financial Officer and Vice President of Finance for
11/19/07
Summary ToggleIRIDEX Reports Third Quarter Financial Results MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the quarter ended September 29, 2007. Revenue for the period was $13.6 million, a 47% increase from the $9.2 million reported for the third quarter of 2006.
11/12/07
Summary ToggleIRIDEX Announces Third Quarter 2007 Conference Call and Release Date MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its third quarter 2007 financial results after the market closes on Monday, November 19, 2007. In conjunction with the release, the Company will host a conference call
10/17/07
Summary ToggleTheodore A. Boutacoff Appointed President & CEO of IRIDEX MOUNTAIN VIEW, Calif., Oct. 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that Barry Caldwell has resigned as the Company's President and Chief Executive Officer, and as a member of the Board of Directors, effective as of October 16, 2007.
10/15/07
Summary ToggleJames B. Hawkins Appointed to IRIDEX Board of Directors Natus Medical CEO Brings More Than 20 Years of Public Company Experience MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today the appointment of James B. Hawkins, president and CEO of Natus Medical, Inc. (Nasdaq: BABY) to its Board of Directors.
10/04/07
Summary ToggleIRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced the appointment of Burr, Pilger & Mayer LLP (BPM) as the Company's new independent auditor effective October 2, 2007. BPM, an independent registered public accounting firm, was approved by the Audit
09/12/07
Summary ToggleWilliam Moore Appointed to IRIDEX Board of Directors Moore is Director at BlueLine Partners, Recent Equity Investors in IRIDEX MOUNTAIN VIEW, Calif., Sept. 12 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today the appointment of William M. Moore to its Board of Directors. Mr. Moore, a director at BlueLine Partners, replaces
09/05/07
Summary ToggleIRIDEX Announces Closing of $5.0 Million Private Placement MOUNTAIN VIEW, Calif., Sept. 5 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has raised $5.0 million in gross proceeds via a private placement conducted with BlueLine Partners which closed on August 31, 2007. Net proceeds after transaction expenses were
08/14/07
Summary ToggleIRIDEX Reports Record Second Quarter Financial Results Revenue rebound from first quarter 2007 to $15.2 million Ophthalmic sales increase 9% year over year to $8.4 million Aesthetic sales increase 28% over first quarter 2007 to $6.9 million MOUNTAIN VIEW, Calif., Aug. 14 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported
08/10/07
Summary ToggleIRIDEX Announces Second Quarter 2007 Conference Call and Release Date MOUNTAIN VIEW, Calif., Aug. 10 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will release its second quarter 2007 financial results after the market closes on Tuesday, August 14, 2007. In conjunction with the release, the Company will host a conference call
08/07/07
Summary ToggleIRIDEX Appoints New Vice President of Quality Assurance and Regulatory Affairs Interim CFO also Appointed MOUNTAIN VIEW, Calif., Aug. 7 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that it has appointed Gary Seeger as its new Vice President of Quality Assurance and Regulatory Affairs. Mr. Seeger, a former Vice President of Quality Assurance (QA) and
07/10/07
Summary ToggleIRIDEX to Present at the 2007 C.E. Unterberg, Towbin Emerging Growth Conference Company Will Comment On First Quarter 2007 Results MOUNTAIN VIEW, Calif., July 10 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it will present at the C.E. Unterberg, Towbin Emerging Growth Conference on Thursday, July 12, 2007 at the Mandarin Oriental in New York
06/08/07
Summary ToggleIRIDEX to Present at the 6th Annual Needham & Company, Biotechnology and Medical Technology Conference MOUNTAIN VIEW, Calif., June 8 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has been invited to present at the 6th Annual Needham & Company Biotechnology and Medical Technology Conference, which will take place at the Palace Hotel in New York City, June 13-14,
05/18/07
Summary ToggleIRIDEX Corporation to Request Nasdaq Hearing Regarding Stock Listing Company Receives Routine Notification after Missing 10-Q Filing Date MOUNTAIN VIEW, Calif., May 18 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported that it plans to request a hearing before the Nasdaq Listing Qualifications Panel following the receipt of the expected
04/10/07
Summary ToggleIRIDEX Announces Settlement of All Litigation with Synergetics IRIDEX to Receive Payments Totaling $6.5 Million Companies Cross License Certain Patents and Sign Supply Agreement MOUNTAIN VIEW, Calif., April 10 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has reached an agreement with Synergetics USA, Inc.
04/03/07
Summary ToggleIRIDEX Reports Fourth Quarter and Full Year 2006 Financial Results MOUNTAIN VIEW, Calif., April 3 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported final financial results for the fourth quarter and full year ended December 30, 2006. "2006 was a very busy, challenging and exciting year for IRIDEX and marked a new phase of development in
04/03/07
Summary ToggleCORRECTION: IRIDEX Reports Fourth Quarter and Full Year 2006 Financial Results In the news release, IRIDEX Reports Fourth Quarter and Full Year 2006 Financial Results, issued earlier today by IRIDEX Corporation over PR Newswire, we are advised by the client that the conference call information has changed. The access numbers for the live conference call should be: (800)
03/29/07
Summary ToggleIRIDEX Reschedules Fourth Quarter and Full Year 2006 Conference Call to April 3 Release Before Market on Tuesday, April 3, 2007; Call at 11:30 a.m. ET MOUNTAIN VIEW, Calif., March 29 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that the Company is rescheduling the release of its fourth quarter and full year 2006 financial results from Friday,
03/27/07
Summary ToggleIRIDEX Announces Fourth Quarter and Full Year 2006 Conference Call MOUNTAIN VIEW, Calif., March 27 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its fourth quarter and full year 2006 financial results at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) on Friday, March 30, 2007.
03/13/07
Summary ToggleCourt Rules on All Remaining Motions in IRIDEX Litigation Four Issues Remain for Trial MOUNTAIN VIEW, Calif., March 13 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that the Hon. Catherine Perry, United States District Judge, has now ruled on all outstanding summary motions in its patent infringement suit against Synergetics
02/28/07
Summary ToggleIRIDEX Announces Option Plan for Acquisition Employees MOUNTAIN VIEW, Calif., Feb. 28 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that in accordance with NASDAQ Marketplace Rule 4350, as amended, the Compensation Committee of IRIDEX's Board of Directors approved the grant of non-qualified stock options to purchase an
02/27/07
Summary ToggleCourt Rules Synergetics Infringes IRIDEX Patent Jury to Decide Amount of Damages in Upcoming Trial MOUNTAIN VIEW, Calif., Feb. 27 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that the Hon. Catherine Perry, United States District Judge, granted summary judgment to IRIDEX on its claim that Synergetics, Inc.'s
02/15/07
Summary ToggleIRIDEX Files Option Plan for CFO MOUNTAIN VIEW, Calif., Feb. 15 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that in accordance with NASDAQ Marketplace Rule 4350, as amended, it granted a non-qualified stock option to Meryl A. Rains, the Company's new Chief Financial Officer, exercisable for 50,000
02/06/07
Summary ToggleIRIDEX Names Meryl Rains Chief Financial Officer Larry Tannenbaum Named to New Position of Chief Business Officer to Focus on Integrating Recently Acquired Laserscope Aesthetics Business and New Business Development MOUNTAIN VIEW, Calif., Feb 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX) today
01/17/07
Summary ToggleIRIDEX Closes Acquisition of Laserscope Aesthetics Business Updates Fourth Quarter 2006 Revenue Forecast Provides Preliminary 2007 Outlook MOUNTAIN VIEW, Calif., Jan. 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has completed the acquisition of the aesthetics business of Laserscope pursuant to the terms of the
01/09/07
Summary ToggleIRIDEX to Present at The 9th Annual Needham & Company, LLC Growth Conference MOUNTAIN VIEW, Calif., Jan. 9 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has been invited to present at the 9th Annual Needham & Company Growth Conference, which will take place at the Palace Hotel in New York City.
12/26/06
Summary ToggleIRIDEX Reports Third Quarter Financial Results Company Files 10Q Reports to Become Current on Its Filings with the SEC US Direct Ophthalmology Revenue Grows 26% for the Quarter Global Direct Ophthalmic Disposable Revenue Grows by 21% Dermatology Revenues Increase MOUNTAIN VIEW, Calif., Dec 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/
12/21/06
Summary ToggleIRIDEX Filing 10Q Reports to Become Compliant With SEC Conference Call to Be Held December 26, 2006 MOUNTAIN VIEW, Calif., Dec. 21 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that it anticipates filing Friday, December 22, 2006, an amended Quarterly Report on Form 10-Q/A for the first quarter of 2006 ended April 1, 2006 as
12/05/06
Summary ToggleIRIDEX to Present at the BMO Capital Markets Focus on Healthcare Conference Management Will Highlight Its Recently Announced Acquisition of the Laserscope Aesthetics Business MOUNTAIN VIEW, Dec. 5 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has been invited to present at the BMO Capital Markets Focus on Healthcare Conference, which will take
11/30/06
Summary ToggleIRIDEX Signs Definitive Agreement to Acquire Laserscope Aesthetics Business Acquisition Expected to Be Accretive to 2007 EPS Prior to Acquisition Costs Sales, Marketing, Manufacturing and Product Innovation Synergies Expected Transaction Should Nearly Double Revenues for 2007 Conference Call Friday, December 1, 2006 at 10:30 AM Eastern Time MOUNTAIN VIEW, Calif., Nov 30,
11/27/06
Summary ToggleIRIDEX Corporation Receives Additional NASDAQ Notice Company Receives Routine Notification After Missing 10-Q Filing Date for the Period Ended September 30, 2006 MOUNTAIN VIEW, Calif., Nov 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX), today reported that, as expected, it has received an additional
11/09/06
Summary ToggleIRIDEX Unveils Two New Laser Systems at the American Academy of Ophthalmology Six New Disposable Products Also Introduced at Academy New Marketing Campaign Launched MOUNTAIN VIEW, Calif., Nov. 9 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of two new ophthalmic laser systems and six new disposable products at the American
10/25/06
Summary ToggleIRIDEX to Present at the C.E. Unterberg, Towbin Life Sciences Conference MOUNTAIN VIEW, Calif., Oct. 25 /PRNewswire/ -- IRIDEX Corporation (NASDAQ/NMS: IRIX) today announced that it has been invited to present at the C.E. Unterberg, Towbin Life Sciences Conference, which will take place at the Palace Hotel in New York City.
08/29/06
Summary ToggleIRIDEX Corporation to Request Nasdaq Hearing Regarding Stock Listing Company Receives Routine Notification After Missing 10-Q Filing Date MOUNTAIN VIEW, Calif., Aug. 29 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported that it plans to request a hearing before the Nasdaq Listing Qualifications Panel following the receipt of the expected
08/03/06
Summary ToggleIRIDEX Reports Second Quarter Financial Results Second Quarter Disposable Revenue Grows 24% Year-Over-Year Gross Margin Increases by almost Five Percentage Points Year-Over-Year GAAP Earning per Share $0.01 Cash Position Increases to $22.3 Million MOUNTAIN VIEW, Calif., Aug. 3 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today
07/25/06
Summary ToggleIRIDEX Announces Second Quarter 2006 Conference Call MOUNTAIN VIEW, Calif., July 25 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its second quarter 2006 financial results after the close of market on Thursday, August 3, 2006. In conjunction with the release, the Company will host a conference
07/10/06
Summary ToggleIRIDEX Receives Positive Ruling in Patent Litigation Against Synergetics MOUNTAIN VIEW, Calif., July 10 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq/NMS: IRIX) announced today that the Court has ruled in favor of IRIDEX regarding claim construction for thirteen of fourteen patent terms involved in the patent infringement action it brought against Synergetics
06/28/06
Summary ToggleIRIDEX Expands Disposable Laser Probe Product Portfolio Continues to Execute Disposable Probe Sales Growth Strategy With New Product Introduction and Patent Application MOUNTAIN VIEW, Calif., June 28 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced the introduction of a family of disposable laser probes called the OtoProbe(TM)
06/21/06
Summary ToggleIRIDEX to Present at the Jefferies Life Sciences Conference MOUNTAIN VIEW, Calif., June 21 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has been invited to present at the Jefferies Life Sciences Conference, which will take place at the Mandarin Oriental Hotel in New York City.
06/07/06
Summary ToggleIRIDEX to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference MOUNTAIN VIEW, Calif., June 7, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has been invited to present at Needham & Company, LLC's Fifth Annual Biotechnology and Medical Technology Conference, which will take place at the New York
06/01/06
Summary ToggleIRIDEX to Present at Pacific Growth Equities Life Sciences Growth Conference MOUNTAIN VIEW, Calif., June 1, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has been invited to present at the Pacific Growth Equities Life Sciences Growth Conference, which will take place at the InterContinental Mark Hopkins
05/15/06
Summary ToggleIRIDEX Reports Strong First Quarter Revenue Growth First Quarter Sales Grow 11% Year-Over-Year to $9.0 Million; Ophthalmology Sales Increase 23%; Disposable Revenues Grows 31%; Sales and Marketing Ophthalmology Programs Gain Traction MOUNTAIN VIEW, Calif., May 15 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial
04/26/06
Summary ToggleIRIDEX Announces First Quarter 2006 Conference Call MOUNTAIN VIEW, Calif., April 26 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its first quarter 2006 financial results after the close of market on May 15, 2006. In conjunction with the release, the Company will host a conference call with the
03/17/06
Summary ToggleIRIDEX Appoints New Vice President of Product Innovation Deborah Tomasco Brings More Than 20 Years of Rapid Product Development and Process Management Expertise to IRIDEX New Marketing Managers Complete Marketing Team MOUNTAIN VIEW, Calif., March 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has appointed Deborah
02/16/06
Summary ToggleIRIDEX Reports Record Fourth Quarter Financial Results Fourth Quarter Revenue Grows 14% to $10.4 Million Full Year 2005 Profit of $0.21 per Share Exceeds Guidance MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported record financial results for the fourth quarter ended December 31, 2005.
02/13/06
Summary ToggleIRIDEX Announces Fourth Quarter and Fiscal Year 2005 Conference Call MOUNTAIN VIEW, Calif., Feb. 13 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its fourth quarter and fiscal year 2005 financial results after the close of market on February 16, 2006. In conjunction with the release, the Company will host a
01/11/06
Summary ToggleIRIDEX Announces Preliminary Fourth Quarter Revenue MOUNTAIN VIEW, Calif., Jan 11, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX) today released preliminary revenue results for the fourth quarter and full-year ended December 31, 2005. The Company is providing these preliminary results due to its scheduled
01/03/06
Summary ToggleIRIDEX to Present at the 8th Annual Needham & Company, LLC Growth Conference MOUNTAIN VIEW, Calif., Jan. 3 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has been invited to present at the 8th Annual Needham & Company, LLC Growth Conference, which will take place at the Palace Hotel in New York City.
10/25/05
Summary ToggleUPDATED - IRIDEX Reports Strong Third Quarter Financial Results Revenue Grows 11%, EPS of $0.11 MOUNTAIN VIEW, Calif., Oct 25, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported strong financial results for the quarter ended October 1, 2005. Revenue for the period was $9.1 million, an 11% increase from the
10/20/05
Summary ToggleIRIDEX to Present at the C. E. Unterberg, Towbin Emerging Growth Life Sciences Conference MOUNTAIN VIEW, Calif., Oct. 20 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX; NMS: IRIX) today announced that it has been invited to present at the C. E. Unterberg, Towbin Emerging Growth Life Sciences Conference, which will take place at the Palace Hotel in New York City.
10/19/05
Summary ToggleIRIDEX Files Suit Against Synergetics USA, Inc. Suit Alleges Infringement of the IRIDEX Disposable Laser Probe Technology MOUNTAIN VIEW, Calif., Oct. 19 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it filed suit on October 19, 2005 against Synergetics USA, Inc. of St.
10/17/05
Summary ToggleIRIDEX Announces Third Quarter 2005 Conference Call MOUNTAIN VIEW, Calif., Oct. 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its third quarter 2005 financial results after market closes on October 25, 2005. In conjunction with the release, the Company will host a conference call with the
10/17/05
Summary ToggleIRIDEX Appoints New Vice President of Marketing Donald J. Todd Brings More Than 30 Years of Sales & Marketing Expertise to IRIDEX MOUNTAIN VIEW, Calif., Oct. 17 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has appointed Donald J. Todd (52) as its new Vice President of Marketing. Mr.
09/26/05
Summary ToggleIRIDEX Expands Product Line with New OcuLight(R) OR Laser for Otological and Ophthalmic Applications MOUNTAIN VIEW, Calif., Sept. 26 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced that it has introduced its new OcuLight OR (532 nm) green laser which expands its existing OcuLight product line offering and allows the Company to enter the Ear, Nose and Throat (ENT) market.
08/03/05
Summary ToggleIRIDEX Reports Improved Second Quarter Financial Results Net Income More Than Triples Revenue Grows 16% MOUNTAIN VIEW, Calif., Aug. 3 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported improved financial results for the quarter ended July 2, 2005. Revenue for the quarter ended July 2, 2005 was $9.4 million, a 16% increase from the
07/21/05
Summary ToggleIRIDEX Announces Second Quarter 2005 Conference Call MOUNTAIN VIEW, Calif., July 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its second quarter 2005 financial results after market closes on August 3, 2005. In conjunction with the release, the Company will host a conference
07/12/05
Summary ToggleIRIDEX Announces Joint Licensing Agreement With Innovatech Surgical for Endophotocoagulation Probes MOUNTAIN VIEW, Calif., July 12, 2005 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced a joint marketing and licensing agreement with Innovatech Surgical, Inc. Under the terms of the arrangement, IRIDEX has an option for worldwide distribution rights to
07/08/05
Summary ToggleIRIDEX Files Option Plan for CEO MOUNTAIN VIEW, Calif., July 8 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that in accordance with NASDAQ Marketplace Rule 4350(i)(1)(A)(iv), as amended, it granted a non-qualified stock option to Barry G. Caldwell, the Company's new Chief Executive Officer, as an
07/05/05
Summary ToggleFormer Alcon(R) Executive, Barry G. Caldwell, Joins Iridex as President and Chief Executive Officer Caldwell a 30+Year Veteran of the Ophthalmic Industry Theodore A. Boutacoff Elected Chairman of the Board MOUNTAIN VIEW, Calif., July 5 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that its Board of Directors has appointed Barry G.
05/03/05
Summary ToggleIRIDEX Announces Confirmation of Favorable Age-Related Macular Degeneration (AMD) Results in TTT4CNV Clinical Trial Sub-Group Additional Follow-up Data Presented MOUNTAIN VIEW, Calif., May 3 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq/NMS: IRIX) today announced that additional follow-up data confirmed a significant clinical benefit in a group of patients with wet age-related macular degeneration (AMD) who were
04/29/05
Summary ToggleIRIDEX Reports First Quarter Results VariLite(TM) Sales Drive 70 Percent Revenue Growth for Dermatology Products; Total Domestic Sales Grow 19 Percent; Gross Margin Improves Leadership; Transition Plan Announced MOUNTAIN VIEW, Calif., April 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX (Nasdaq: IRIX) announced sales for the
04/25/05
Summary ToggleIRIDEX Announces First Quarter 2005 Conference Call MOUNTAIN VIEW, Calif., April 25 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its first quarter 2005 financial results before market opens on April 29, 2005. In conjunction with the release, the Company will host a conference call with the
02/24/05
Summary ToggleIRIDEX Announces Favorable TTT4CNV Clinical Trial Sub-Group Results Company to Host Conference Call to Discuss Results on Monday, February 28, 1:30 p.m. ET, 10:30 a.m. PT MOUNTAIN VIEW, Calif., Feb 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced a significant clinical benefit in a subset of patients with wet
02/15/05
Summary ToggleIRIDEX Reports Fourth Quarter Results Dermatology Quarterly Product Revenues Increase 20% Full Year 2004 International Sales Increase 11% MOUNTAIN VIEW, Calif., Feb 15, 2005 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX (Nasdaq: IRIX) announced sales for the fourth quarter ended January 1, 2005 of $9.1 million, up 4% from $8.8 million
02/07/05
Summary ToggleIRIDEX to Move 2004 Fourth Quarter and Full Year Results Release Date MOUNTAIN VIEW, Calif., Feb 07, 2005 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX), today announced that it is moving the results release date for the fourth quarter and full year ended January 1, 2005. The release date was originally scheduled for February 8, 2005 and is
10/22/04
Summary ToggleIRIDEX Announces Presentation of Preliminary Results of TTT4CNV Clinical Trial for Patients With Age-related Macular Degeneration MOUNTAIN VIEW, Calif., Oct. 22 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that Dr. Elias Reichel presented preliminary two-year results from the TTT4CNV Clinical Trial for occult neovascular (wet) age-related macular degeneration (AMD).
10/19/04
Summary ToggleIRIDEX Reports Third Quarter Operating Performance MOUNTAIN VIEW, Calif., Oct. 19 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported results for the quarter ended October 2, 2004. Revenue for the quarter decreased 1.1% to $8.2 million from $8.3 million reported for the third quarter a year ago that ended September 27, 2003.
10/13/04
Summary ToggleIRIDEX Announces Third Quarter 2004 Conference Call MOUNTAIN VIEW, Calif., Oct 13, 2004 /PRNewswire-FirstCall via COMTEX/ -- IRIDEX Corporation (Nasdaq: IRIX) announced that the Company will release its third quarter 2004 financial results after the close of market on October 19, 2004. In conjunction with the release, the Company will host a
10/13/04
Summary ToggleIRIDEX Receives FDA Clearance for New IRIS Medical(R) IQ 810(TM) Infrared Laser MOUNTAIN VIEW, Calif., Oct. 13 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced 510(k) clearance from the Food & Drug Administration (FDA) for the new solid-state IRIS Medical IQ 810 infrared diode laser photocoagulator for the treatment of retinal disorders and glaucoma.
10/07/04
Summary ToggleIRIDEX Announces FDA Clearance for New VariLite(TM) Dual Wavelength Laser MOUNTAIN VIEW, Calif., Oct. 7 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) announced today that it has received 510(k) clearance from the Food & Drug Administration (FDA) for its new VariLite dual wavelength laser. The VariLite was cleared for 19 specific dermatology indications
09/24/04
Summary ToggleGarrett Garrettson Elected to IRIDEX Board of Directors MOUNTAIN VIEW, Calif., Sept. 24 /PRNewswire-FirstCall/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that its Board of Directors has elected Garrett A. Garrettson (age 61) to the Company's Board. Dr. Garrettson will fill the current vacancy on the Board and will become the seventh member of
07/27/04
Summary ToggleIRIDEX REPORTS IMPROVED SECOND QUARTER OPERATING PERFORMANCE For Immediate Release Contact: Larry Tannenbaum Chief Financial Officer 650-940-4700 IRIDEX REPORTS IMPROVED SECOND QUARTER OPERATING PERFORMANCE Revenue Increases 9.1% Net Income of $0.02 per Share Cash Position Increases to All Time High of $18.5 Million MOUNTAIN VIEW, CA, JULY 27, 2004---IRIDEX
07/16/04
Summary ToggleIRIDEX Announces Second Quarter 2004 Conference Call IRIDEX Corporation (NASDAQ/NMS:IRIX) announced that the Company will release its second quarter 2004 financial results after the close of market on July 27, 2004. In conjunction with the release, the Company will host a conference call with the investment community at 2:00 p.m.
05/04/04
Summary ToggleIRIDEX Reports First Quarter Results For Immediate Release Contact: Larry Tannenbaum Chief Financial Officer (650) 940-4700 May 4, 2004 Mountain View, California IRIDEX Reports First Quarter Results · Wet AMD clinical study results likely in Q4 2004 · Strong international ophthalmology revenues · “Cash” increases to nearly $17 million
04/26/04
Summary ToggleIRIDEX Announces First Quarter 2004 Conference Call IRIDEX Corporation (NASDAQ/NMS:IRIX) announced that the Company will release its first quarter 2004 financial results after the close of market on May 4, 2004. In conjunction with the release, the Company will host a conference call with the investment community at 2:00 p.m.
04/07/04
Summary ToggleSANFORD FITCH ELECTED TO IRIDEX BOARD OF DIRECTORS MOUNTAIN VIEW, Calif. – April 7, 2004 – IRIDEX Corporation (NASDAQ/NMS:IRIX) today announced that its board of directors has elected Sanford “Sandy” Fitch (age 63) to the Company's board, where he will serve as the Chair of the Audit and Corporate Governance Committee. Mr.
02/04/04
Summary ToggleIRIDEX Reports Profitable Fourth Quarter and Full Year IRIDEX (NASDAQ/NMS:IRIX) announced sales for the fourth quarter ended January 3, 2004 of $8.8 million, down from $9.5 million in the corresponding 2002 quarter. Sales for the fourth quarter 2002 included a significant initial OEM stocking order for the Millennium EndoLase™ module sold by Bausch &
01/27/04
Summary ToggleIRIDEX Announces Fourth Quarter and Fiscal Year 2003 Conference Call IRIDEX Corporation (NASDAQ/NMS:IRIX) announced that the Company will release its fourth quarter and fiscal year 2003 financial results after the close of market on February 4, 2004. In conjunction with the release, the Company will host a conference call with the investment community at 2:00 p.m.
12/22/03
Summary ToggleIRIDEX Announces TTT Laser Treatment of Wet AMD Approved for Medicare Reimbursement in Pennsylvania 16 States Now Reimburse for TTT IRIDEX Corporation (NASDAQ/NMS:IRIX) announced that HGSAdministrators (HGSA), the Medicare Part B Carrier for Pennsylvania, published a Local Medical Review Policy (LMRP) that will allow reimbursement to ophthalmologists performing Transpupillary Thermotherapy (TTT)